

Jul 2018

CURRICULUM VITAE

NAME SUN YOUNG RHA, M.D., Ph.D.

BIRTH DATE February 9, 1966

ADDRESS Yonsei Cancer Center, Yonsei University College of Medicine
50-1 Yonsei-ro, Seodaemun-Ku
Seoul, KOREA 03722

POSITION Professor, Medical Oncology, Department of Internal Medicine
Vice-director, Songdang Institute for Cancer Research, Yonsei
University College of Medicine
Director, Human Research Protection Center, Severance Hospital,
Yonsei University Health System, Seoul, Korea
Chair, Academic Committee of Korean Cancer Society (KCA)
Executive Board Member and chair of Translational Research
Committee, Korean Cancer Study Group
Executive Board Member of Korean Gastric Cancer Society
Chair, Planning Committee of Korean Association of IRB

CITIZENSHIP KOREAN

LICENCES AND QUALIFICATIONS

- 1990 Doctor of Medicine and License of General Medicine –Korea (#42774)
- 1995 Specialty in Internal Medicine in Korea (# 4504)
- 1997 Subspecialty in Hematology/Oncology - Korea
- 1998 USMLE/ECFMG (0-561-228-8)

EDUCATION

- 1984-1986 Department of Pre-medical Science
Yonsei University College of Science
Seoul, Korea
- 1986-1990 Yonsei University College of Medicine
Seoul, Korea
- 1990-1991 Rotating Internship
Yonsei University College of Medicine
Yonsei Medical Center, Severance Hospital
Seoul, Korea
- 1991-1995 Residency in Internal Medicine
Yonsei University College of Medicine
Yonsei Medical Center, Severance Hospital
Seoul, Korea
- 1991-1997 Graduate School
Yonsei University College of Medicine
Seoul, Korea

Thesis: "Studies on the anti-tumor effect of growth factor inhibitors and anti-metastasis agents in human gastric cancer cell lines."

PROFESSIONAL BACKGROUND AND EXPERIENCE

- 2011- Professor, Medical Oncology, Internal Medicine
Yonsei University College of Medicine, Seoul, KOREA
- 2009- Present Director, Human research Protection Center, Severance Hospital
- 2006- Present Chief, Division of Genomics and Translational Research,
Cancer Metastasis Research Center, Yonsei University College of Medicine
- 2007 - 2010 Associate Professor, Medical Oncology, Internal Medicine
Yonsei University college of Medicine, Seoul, KOREA
- 2006 - 2007 Associate Professor, Medical Oncology, Internal Medicine, Yonsei Cancer Center
- 2006-2009 Head, Division of Clinical Trial Support, Education and Training,
Clinical Trials Center, Yonsei University college of Medicine, Seoul, KOREA
- 2005 - 2009 Secretary General of Severance Hospital IRB,
Yonsei University College of Medicine, Seoul, Korea
- 2001 - 2005 Assistant professor
Cancer Metastasis Research Center
Yonsei Cancer Center, Yonsei University College of Medicine
Seoul, KOREA
- 1998 – 2000 Clinical and Research Fellow in Medical Oncology
Division of Hemato-Oncology, Department of Medicine
Cancer Therapy and Research Center
Institute for Drug Development
The University of Texas Health Science Center at San Antonio
San Antonio, Texas
- 1995 - 1998 Clinical and Research Fellowship in Medical Oncology
Division of Hemato-Oncology
Department of Medicine
Yonsei Cancer Center
Yonsei Cancer Research Institute
Yonsei University College of Medicine
Seoul, Korea

MEMBERSHIP

1991	Korean Association of Internal Medicine
1993	Korean Cancer Association
1994	Korean Society of BRM/Immunology
1995	Korean Society of Clinical Pharmacology
1995	Korean Society of Head & Neck Oncology
1995	American Association for Cancer Research (Associate member)
1997	AACR (Corresponding member)
1997	American Society of Clinical Oncology (Active member)
2000	Korean Human Proteomics (KHUPO)
2001	Korean Genome Organization (KOGO) Korean Cancer Study Group
2002	Korean Society for Bioinformatics Korean Society of Angiogenesis
2003	Korean Society of Gastric Cancer Korean Society of Breast cancer
2004	Korea Association of Institutional Review Board
2005	Korean Association for Clinical Oncology
2008	Connective Tissue Oncology Society

AWARDS

1997	Outstanding Research Paper Award The Graduate School of Yonsei University, Seoul, Korea
1998	American Cancer Society International Fellowship Award UICC (International Union against Cancer)
1998	SB Fellow Sponsorship, Smith Kline Beecham Korea
1999	Young Investigator Award AACR-NCI-EORTC International Conference
2001	Excellence in Research Grant Yonsei University College of Medicine
2005	Research Award for 2005 ASCO Korean Cancer Study Group, Korean Cancer Society
2005	Outstanding Paper Award Yonsei University College of Medicine, Seoul, Korea
2006	Excellent Accomplish Award, Yonsei University
2008	Outstanding Research Paper Award, The Korean Federation of Science and Technology Society
2010	10 th Sanofi-Aventis Research Award, Korean Cancer Association
2011	Roche Research Award, Korean Cancer Association
2012	Award for the Best Research Performance, Yonsei University
2013	13 th Sanofi-Aventis Research Award, Korean Cancer Association

PATENTS

1. Method for Selecting Gastric Cancer Specific Predictor Genes, 2007.4.30
2. Paclitaxel sensitivity predictive genes in gastric cancer cell lines, 2012.5.15
3. Diagnostic genetic marker for Human Mucinous Colorectal Cancer, 2012.08.24
4. Diagnostic kit for human colorectal cancer, 2013.2.5

RESEARCH GRANTS

On-Going Research Support

1. Clinical implementation of precision cancer medicine, from The Ministry of Health and Welfare, Korea 2013/12/1 – 2018/11/30 (PI)
2. Biomarker-driven Umbrella trial for triple negative gastric cancer, from The Ministry of Health and Welfare through National Cancer Control Planning Board, Korea 2015/10/1 – 2020/8/30 (PI)
3. Smart integration strategy of overcoming tumor heterogeneity and modulation of immune microenvironment in gastric peritoneal carcinomatosis, by Basic Science Research Program through the National Research Foundation of Korea(NRF) funded by the Ministry of Science, ICT & Future Planning 2017/5/1 – 2020/8/30 (PI)
4. Proteogenomics approaches for biomarker discovery and drug development in renal cell carcinoma, from from The Ministry of Health and Welfare through National Cancer 2018/5/1 – 2022/12/30 (PI)

Completed Research Support

1. M1-0106-00-0060 from Korea Ministry of Science and Technology, 8/1/2001-5/30/2004, Identification of cancer treatment related genes and new treatment algorithm based on functional genomics (Role: PI)
유방암에서 기능성 유전체 연구에 의한 항암제 감수성 유전자 발굴과 이에 근거한 치료 기술 개발
2. 02-PJ1-PG10-20802-0011 from The Ministry of Health and Welfare, Korea, 5/1/2002-4/30/2004, Molecular markers for tumor response and toxicity to preoperative chemoradiation treatment in patients with locally advanced rectal cancer (Role: Co-PI)
3. Lilly Inc. Research Grant 3/1/2002- 2/28/2004, Changes of gene expression profiling of breast cancer with gemcitabine treatment (Role: PI)
4. 01-PJ11-PG9-01BT00A-0028 the Ministry of Health & Welfare, as a IMT-2000 project, 12/1/2001-11/30-2003, Development of Genechip for Colorectal Cancer Based on Functional Genomics & Proteomics (Role: PI)
5. 01-PJ4-PG4-01VN01-0276 from Korea Ministry of Science and Technology, 12/1/2001-3/31/2003, Construction of universal human reference RNA for human cDNA chip experiment and expression profiling of tissue-specific genes (Role: Co-PI)
6. Yonsei University Research Grant, 7/1/2001-6/30/2002, Molecular profiling of cancer cell lines(Role: PI)
7. Merck Korea Research Grant, Evaluation of *in vivo* efficacy of SAHA-new formula in gastric cancer, 03/01/2006-03/01/2008 (Role: PI)
8. Scientific Research Center Project from the Korea Science and Engineering Foundation, 3/1/2001 – 2/28/2008, Functional genomics in tumor angiogenesis (Role: PI)
9. KRF-2005-005-J05904 from the Korea Research Foundation through Oral Cancer Research Institute, Yonsei University, 12/1/2005-2/28/2007, Cancer prevention based on biological characteristics of carcinogenesis. (Role: Co-PI)

10. Sanofi-Aventis Research Grant through BK-21 Yonsei University College of Medicine, Korea. ADAM-9 as a novel target in gastric cancer,03/01/2008-02/28/2009 (Role: PI)

11. Yonsei Medical College Faculty Grant, Development of biomarker-based individualized therapeutic strategies in gastric cancer 09/01/2007-08/31/2009 (Role: PI)

12. Janssen Inc. Research Grant through BK-21 Yons2014 Jul 24;12:232, Yonsei University College of Medicine, Korea. Sarcoma Registry, 12/01/2008-11/31/2009 (Role: PI)

13. Project of Yonsei Medical Science, 4/16/2010-4/15/2011 Identification of liver metastasis predictors in gastric cancer (Role: PI)

14. 0405-BC01-0604-0002 from The Ministry of Health and Welfare, Korea, 5/1/2004-4/1/2013, DNA chip system development center for diagnosis and prognosis prediction of colorectal cancer (Role: Co-PI)

15. Study on identification of molecular characteristics of geriatric cancer through high-throughput genomics and epigenetics technology, from The Ministry of Health and Welfare, Korea, 7/1/2010-6/30/2016 (PI)

PUBLICATIONS (1996~2018)

1. [The clinical implications of FDG-PET/CT differ according to histology in advanced gastric cancer.](#) Chon HJ, Kim C, Cho A, Kim YM, Jang SJ, Kim BO, Park CH, Hyung WJ, Ahn JB, Noh SH, Yun M, **Rha SY**. Gastric Cancer. 2018 Jun 9. doi: 10.1007/s10120-018-0847-5. [Epub ahead of print]
2. [CpG Island Methylator Phenotype and Methylation of Wnt Pathway Genes Together Predict Survival in Patients with Colorectal Cancer.](#) Kim SH, Park KH, Shin SJ, Lee KY, Kim TI, Kim NK, **Rha SY**, Ahn JB. Yonsei Med J. 2018 Jul;59(5):588-594. doi: 10.3349/ymj.2018.59.5.588.
3. [A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy.](#) Chae D, Nam CM, Kim JH, Lee CK, Kim SS, Kim HS, Jung M, Cheong JH, Chung HC, **Rha SY**, Park K. APS J. 2018 May 29;20(4):72. doi: 10.1208/s12248-018-0223-8.
4. [MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis.](#) Kim HS, Chon HJ, Kim H, Shin SJ, Wacheck V, Gruver AM, Kim JS, **Rha SY**, Chung HC. J Surg Oncol. 2018 May 22. doi: 10.1002/jso.25097. [Epub ahead of print]
5. [Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial.](#) Guo J, Jin J, Oya M, Uemura H, Takahashi S, Tatsugami K, **Rha SY**, Lee JL, Chung J, Lim HY, Wu HC, Chang YH, Azad A, Davis ID, Carrasco-Alfonso MJ, Nanua B, Han J, Ahmad Q, Motzer R. J Hematol Oncol. 2018 May 22;11(1):69. doi: 10.1186/s13045-018-0617-1.
6. 'Screening audit' as a quality assurance tool in good clinical practice compliant research environments. Park S, Nam CM, Park S, Noh YH, Ahn CR, Yu WS, Kim BK, Kim SM, Kim JS, Rha SY. BMC Med Ethics. 2018 Apr 25;19(1):30. doi: 10.1186/s12910-018-0269-2.

7. Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients. Lee SH, Lee B, Shim JH, Lee KW, Yun JW, Kim SY, Kim TY, Kim YH, Ko YH, Chung HC, Yu CS, Lee J, Rha SY, Kim TW, Jung KH, Im SA, Moon HG, Cho S, Kang JH, Kim J, Kim SK, Ryu HS, Ha SY, Kim JI, Chung YJ, Kim C, Kim HL, Park WY, Noh DY, Park K. *Cancer Res Treat*. 2018 Apr 23. doi: 10.4143/crt.2018.132. [Epub ahead of print]
8. A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer. Sundar R, **Rha SY**, Yamaue H, Katsuda M, Kono K, Kim HS, Kim C, Mimura K, Kua LF, Yong WP. *BMC Cancer*. 2018 Mar 27;18(1):332. doi: 10.1186/s12885-018-4234-8
9. Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus IV paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy. Kang YK, Ryu MH, Park SH, Kim JG, Kim JW, Cho SH, Park YL, Park SR, **Rha SY**, Kang MJ, Cho JY, Kang SY, Roh SY, Ryoo BY, Nam BH, Jo YW, Yoon KE, Oh SC. *Ann Oncol*. 2018 Feb 9. doi: 10.1093/annonc/mdy055. [Epub ahead of print].
10. Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor. Kim HJ, Kang SK, Kwon WS, Kim TS, Jeong I, Jeung HC, Kragh M, Horak ID, Chung HC, **Rha SY**. *Int J Cancer*. 2018 Feb 13. doi: 10.1002/ijc.31304. [Epub ahead of print].
11. Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). Jung M, Ryu MH, Oh DY, Kang M, Zang DY, Hwang IG, Lee KW, Kim KH, Shim BY, Song EK, Sym SJ, Han HS, Park YL, Kim JS, Lee HW, Lee MH, Koo DH, Song HS, Lee N, Yang SH, Choi DR, Hong YS, Lee KE, Maeng CH, Baek JH, Kim S, Kim YH, **Rha SY**, Cho JY, Kang YK. *Gastric Cancer*. 2018 Feb 9. doi: 10.1007/s10120-018-0806-1. [Epub ahead of print].
12. Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma. Cho YJ, Kim SH, Kim EK, Han JW, Shin KH, Hu H, Kim KS, Choi YD, Kim S, Lee YH, Suh JS, Ahn JB, Chung HC, Noh SH, **Rha SY**, Jung ST, Kim HS. *BMC Cancer*. 2018 Feb 7;18(1):158. doi: 10.1186/s12885-018-4066-6. [Epub ahead of print].
13. S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial. Lee CK, Jung M, Kim HS, Jung I, Shin DB, Kang SY, Zang DY, Kim KH, Lee MH, Kim BS, Lee KH, Cheong JH, Hyung WJ, Noh SH, Chung HC, **Rha SY**. *Cancer Res Treat*. 2018 Feb 5. doi: 10.4143/crt.2018.28. [Epub ahead of print].
14. Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Knox JJ, Barrios CH, Kim TM, Cosgriff T, Srimuninnimit V, Pittman K, Sabbatini R, **Rha SY**, Flaig TW, Page RD, Beck JT, Cheung F, Yadav S, Patel P, Geoffrois L, Niolat J, Berkowitz N, Marker M, Chen D, Motzer RJ. *Ann Oncol*. 2018 Jan 29. doi: 10.1093/annonc/mdx807. [Epub ahead of print].

15. Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11. Kim HS, Ryu MH, Zang DY, Park SR, Han B, Kang WK, **Rha SY**, Jung M, Kim JS, Kang BW, Lee KH, Rho SY, Kim JH, Kim KC, Cho JW, Choi DR, Lim H, Kang HS, Soh JS, Kim MJ, Seo J, Kang YK. *Gastric Cancer*. 2018 Jan 25. doi: 10.1007/s10120-018-0794-1. [Epub ahead of print].
16. PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer. Kim C, Lee CK, Chon HJ, Kim JH, Park HS, Heo SJ, Kim HJ, Kim TS, Kwon WS, Chung HC, **Rha SY**. *Oncotarget* 2017 Dec 9;8(69):113494-113501
17. Rab25 augments cancer cell invasiveness through a β 1 integrin/EGFR/VEGF-A/Snail signaling axis and expression of fascin. Jeong BY, Cho KH, Jeong KJ, Park YY, Kim JM, **Rha SY**, Park CG, Mills GB, Cheong JH, Lee HY. *Exp Mol Med*. 2018 Jan 26;50(1):e435. doi: 10.1038/emmm.2017.248.
18. Genetic Alterations among Korean Melanoma Patients Showing Tumor Heterogeneity: A Comparison between Primary Tumors and Corresponding Metastatic Lesions. Lee SH, Kim JE, Jang HS, Park KH, Oh BH, Shin SJ, Chung KY, Roh MR, **Rha SY**. *Cancer Res Treat*. 2018 Jan 22. doi: 10.4143/crt.2017.535. [Epub ahead of print].
19. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Bang YJ, Xu RH, Chin K, Lee KW, Park SH, **Rha SY**, Shen L, Qin S, Xu N, Im SA, Locker G, Rowe P, Shi X, Hodgson D, Liu YZ, Boku N. *Lancet Oncol*. 2017 Dec;18(12):1637-1651.
20. Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer. Soo Park J, Youn JC, Shim CY, Hong GR, Lee CK, Kim JH, Park HS, Heo SJ, Beom SH, Kim HS, **Rha SY**, Chung HC, Kang SM, Jung M. *Oncotarget*. 2017 Jun 27;8(37):61837-61845.
21. A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma. Voss MH, Hussain A, Vogelzang N, Lee JL, Keam B, **Rha SY**, Vaishampayan U, Harris WB, Richey S, Randall JM, Shaffer D, Cohn A, Crowell T, Li J, Senderowicz A, Stone E, Figlin R, Motzer RJ, Haas NB, Hutson T. *Ann Oncol*. 2017 Nov 1;28(11):2754-2760.
22. Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer. Jeung HC, **Rha SY**, Shin SJ, Ahn JB, Park KH, Kim TS, Kim JJ, Roh JK, Chung HC. *Oncol Lett*. 2017 Aug;14(2):2385-2392.
23. A randomized phase 2 trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma. Voss MH, Hussain A, Vogelzang N, Lee JL, Keam B, **Rha SY**, Vaishampayan U, Harris WB, Richey S, Randall JM, Shaffer D, Cohn A, Crowell T, Li J, Senderowicz A, Stone E, Figlin R, Motzer RJ, Haas NB, Hutson T. *Ann Oncol*. 2017 Sep 11. doi:

10.1093/annonc/mdx493. [Epub ahead of print].

24. A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. Mateo J, Ganji G, Lemech C, Burris HA, Han SW, Swales K, Decordova S, DeYoung MP, Smith DA, Kalyana-Sundaram S, Wu J, Motwani M, Kumar R, Tolson JM, **Rha SY**, Chung HC, Eder JP, Sharma S, Bang YJ, Infante JR, Yan L, de Bono JS, Arkenau HT. Clin Cancer Res. 2017 Oct 1;23(19):5981-5992.
25. The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status. Park JS, Lee N, Beom SH, Kim HS, Lee CK, **Rha SY**, Chung HC, Yun M, Cho A, Jung M. Gastric Cancer. 2018 Mar;21(2):213-224.
26. Pazopanib for the Treatment of Non-Clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study. Jung KS, Lee SJ, Park SH, Lee JL, Lee SH, Lim JY, Kang JH, Lee S, **Rha SY**, Lee KH, Kim HY, Lim HY. Cancer Res Treat. 2017 May 22. doi: 10.4143/crt.2016.584. [Epub ahead of print].
27. Integration of radiotherapy and chemotherapy for abdominal lymph node recurrence in gastric cancer. Lee J, Yoon HI, **Rha SY**, Hyung WJ, Lee YC, Lim JS, Kim HS, Koom WS. Clin Transl Oncol. 2017 Oct;19(10):1268-1275.
28. Prevalence and prognostic implications of psychological distress in patients with gastric cancer. Kim GM, Kim SJ, Song SK, Kim HR, Kang BD, Noh SH, Chung HC, Kim KR, **Rha SY**. BMC Cancer. 2017 Apr 20;17(1):283. doi: 10.1186/s12885-017-3260-2. [Epub ahead of print] .
29. The Benefit of Pro Re Nata Antiemetics Provided With Guideline-Consistent Antiemetics in Delayed Nausea Control. **Rha SY**, Sohn J, Kim GM, Kim HR, Lee J. Cancer Nurs. Cancer Nurs. 2018 Mar/Apr;41(2):E49-E57.
30. A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors. Kim GM, Reid T, Shin SJ, **Rha SY**, Ahn JB, Lee SS, Chung HC. Invest New Drugs. 2017 Mar 28. doi: 10.1007/s10637-017-0460-1. [Epub ahead of print].
31. Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. Albiges L, Hakimi AA, Xie W, McKay RR, Simantov R, Lin X, Lee JL, Rini BI, Srinivas S, Bjarnason GA, Ernst S, Wood LA, Vaishamayan UN, **Rha SY**, Agarwal N, Yuasa T, Pal SK, Bamias A, Zabor EC, Skanderup AJ, Furberg H, Fay AP, de Velasco G, Preston MA, Wilson KM, Cho E, McDermott DF, Signoretti S, Heng DY, Choueiri TK. J Clin Oncol. 2016 Sep 6. pii: JCO667311. [Epub ahead of print].

32. Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee. Kim MJ, Kim YS, Oh SY, Lee S, Choi YJ, Seol YM, Park MJ, Kim KH, Park LC, Kang JH, Hwang IG, Lee SI, Lim ST, Kim HS, Lim HY, **Rha SY**, Kim HJ. Korean J Intern Med. 2016 Apr 6. [Epub ahead of print].
33. Modulation of HAT activity by the BRCA2 N372H variation is a novel mechanism of paclitaxel resistance in breast cancer cell lines. Kwon WS, **Rha SY**, Jeung HC, Kim TS, Chung HC. Biochem Pharmacol. 2017 Aug 15; 138-173. doi: 10.1016/j.bcp.2017.4.15.
34. Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer. Soo Park J, Youn JC, Shim CY, Hong GR, Lee CK, Kim JH, Park HS, Heo SJ, Beom SH, Kim HS, **Rha SY**, Chung HC, Kang SM, Jung M. Oncotarget. 2017 Jun 27;8(37):61837-61845.
35. Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer. Jeung HC, **Rha SY**, Shin SJ, Ahn JB, Park KH, Kim TS, Kim JJ, Roh JK, Chung HC. Oncol Lett. 2017 Aug;14(2):2385-2392. doi: 10.3892/ol.2017.6438.
36. Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma. Qamra A, Xing M, Padmanabhan N, Kwok JJT, Zhang S, Xu C, Leong YS, Lee Lim AP, Tang Q, Ooi WF, Suling Lin J, Nandi T, Yao X, Ong X, Lee M, Tay ST, Keng ATL, Gondo Santoso E, Ng CCY, Ng A, Jusakul A, Smoot D, Ashktorab H, **Rha SY**, Yeoh KG, Peng Yong W, Chow PKH, Chan WH, Ong HS, Soo KC, Kim KM, Wong WK, Rozen SG, Teh BT, Kappei D, Lee J, Connolly J, Tan P. Cancer Discov. 2017 Jun;7(6):630-651. doi: 10.1158/2159-8290.CD-16-1022.
37. Locoregional relapse after gastrectomy with D2 lymphadenectomy for gastric cancer. Chang JS, Kim KH, Yoon HI, Hyung WJ, **Rha SY**, Kim HS, Lee YC, Lim JS, Noh SH, Koom WS. Br J Surg. 2017 Jun;104(7):877-884.
38. Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer. Kim HS, Lee H, Shin SJ, Beom SH, Jung M, Bae S, Lee EY, Park KH, Choi YY, Son T, Kim HI, Cheong JH, Hyung WJ, Park JC, Shin SK, Lee SK, Lee YC, Koom WS, Lim JS, Chung HC, Noh SH, **Rha SY**, Kim H, Paik S. Oncotarget. 2017 Jun 13; 8(24):38389-38398. doi: 10.18632/oncotarget.16409.
39. Final overall survival analysis for the phase II RECORD-3 Study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Knox JJ, Barrios CH, Kim TM, Cosgriff T, Srimuninnimit V, Pittman K, Sabbatini R, **Rha SY**, Flaig TW, Page RD, Beck JT, Cheung F, Yadav S, Patel P, Geoffrois L, Niolat J, Berkowitz N, Marker M, Chen D, Motzer RJ. Ann Oncol. 2017 Jun 1;28(6):1339-1345. doi: 10.1093/annonc/mdx075.

40. Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma. De Velasco G, Xie W, Donskov F, Albiges L, Beuselinck B, Srinivas S, Agarwal N, Lee JL, Brugarolas J, Wood LA, **Rha SY**, Kollmannsberger C, North S, Kanesvaran R, Rini BI, Broom R, Yamamoto H, Kaymakcalan MD, Heng DY, Choueiri TK. Clin Genitourin Cancer. 2017 Jun;15(3):403-410.e2.
41. Symptom clusters during palliative chemotherapy and their influence on functioning and quality of life. **Rha SY**, Lee J. Support Care Cancer. 2017 May;25(5):1519-1527. doi: 10.1007/s00520-016-3545-z.
42. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents. Hwang SH, Cho A, Yun M, Choi YD, **Rha SY**, Kang WJ. Clin Nucl Med. 2017 May;42(5):e235-e241. doi: 10.1097/RLU.1612.
43. Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma: Stage Adjusted Analysis From a Single High-volume Center in Asia. Chon HJ, Hyung WJ, Kim C, Park S, Kim JH, Park CH, Ahn JB, Kim H, Chung HC, **Rha SY**, Noh SH, Jeung HC. Ann Surg. 2017 May; 265(5):946-953.
44. Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab. Lee CK, Kim SS, Park S, Kim C, Heo SJ, Lim JS, Kim H, Kim HS, **Rha SY**, Chung HC, Park S, Jung M. Oncotarget. 2017 May 9;8(19):31169-31179. doi: 10.18632/oncotarget.16099.
45. Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma: Stage Adjusted Analysis From a Single High-volume Center in Asia. Chon HJ, Hyung WJ, Kim C, Park S, Kim JH, Park CH, Ahn JB, Kim H, Chung HC, **Rha SY**, Noh SH, Jeung HC. Ann Surg. 2017 May;265(5):946-953. doi: 10.1097/SLA.1793.
46. Characterizing the outcomes of metastatic papillary renal cell carcinoma. Connor Wells J, Donskov F, Fraccon AP, Pasini F, Bjarnason GA, Beuselinck B, Knox JJ, **Rha SY**, Agarwal N, Bowman IA, Lee JL, Pal SK, Srinivas S, Scott Ernst D, Vaishampayan UN, Wood LA, Simpson R, De Velasco G, Choueiri TK, Heng DYC. Cancer Med. 2017 May;6(5):902-909. doi: 10.1002/cam4.1048.
47. Different subtypes of epithelioid sarcoma and their clinical implication: long-term multi-institutional experience with a rare sarcoma. Kim C, Yoo KH, Kim MH, Chon HJ, Lee SI, Lee HJ, Koh S, Lee HY, Lee HR, Kim KS, Choi YD, **Rha SY**, Lee SJ, Kim HS. APMIS. 2017 Mar;125(3):223-229. doi: 10.1111/apm.12656.
48. ABCB1 2677G>T/A variant enhances chemosensitivity to anti-cancer agents acting on microtubule dynamics through LAMP1 inhibition. Kwon WS, **Rha SY**, Jeung HC, Ahn JB, Jung JJ, Ki DH, Kim TS, Chung HC. Biochem Pharmacol. 2017 Jan 1;123:73-84. doi: 10.1016/j.bcp.2016.11.5.

49. Telomerase reverse transcriptase (TERT) promoter mutations in Korean melanoma patients. Roh MR, Park KH, Chung KY, Shin SJ, **Rha SY**, Tsao H. *Am J Cancer Res.* 2017 Jan 1;7(1):134-138.
50. Recursive partition analysis of peritoneal and systemic recurrence in patients with gastric cancer who underwent D2 gastrectomy: Implications for neoadjuvant therapy consideration. Chang JS, Kim KH, Keum KC, Noh SH, Lim JS, Kim HS, **Rha SY**, Lee YC, Hyung WJ, Koom WS. *J Surg Oncol.* 2016 Dec;114(7):859-864.
51. Epstein-Barr virus BARP1-induced NFκB/miR-146a/SMAD4 alterations in stomach cancer cells. Kim DH, Chang MS, Yoon CJ, Middeldorp JM, Martinez OM, Byeon SJ, **Rha SY**, Kim SH, Kim YS, Woo JH. *Oncotarget.* 2016 Dec 13;7(50):82213-82227.
52. Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithm. Park CK, Park JS, Kim HS, **Rha SY**, Hyung WJ, Cheong JH, Noh SH, Lee SK, Lee YC, Huh YM, Kim H. *Oncotarget.* 2016 Nov 1;7(44):72099-72112.
53. Gaps exist between patients' experience and clinicians' awareness of symptoms after chemotherapy: CINV and accompanying symptoms. **Rha SY**, Song SK, Lee CE, Park Y, Lee J. *Support Care Cancer.* 2016 Nov;24(11):4559-66.
54. ADAR-mediated RNA editing predicts progression and prognosis of Gastric Cancer. Chan TH, Qamra A, Tan KT, Guo J, Yang H, Qi L, Lin JS, Ng VH, Song Y, Hong H, Tay ST, Liu Y, Lee J, **Rha SY**, Feng Z, So JB, Bin Tean T, Guan YK, Rozen S, Tenen DG, Tan P, Chen L. *Gastroenterology.* 2016 Oct;151(4):637-650.
55. Efficacy and Toxicity of Mammalian Target Rapamycin Inhibitors in Patients with Metastatic Renal Cell Carcinoma with Renal Insufficiency: The Korean Cancer Study Group GU 14-08. Kim KH, Kim JH, Lee JY, Kim HS, Heo SJ, Kim JH, Kim HY, **Rha SY**. *Cancer Res Treat* 2016 Oct;48(4):1286-1292..
56. Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity. Ooi WF, Xing M, Xu C, Yao X, Ramlee MK, Lim MC, Cao F, Lim K, Babu D, Poon LF, Lin Suling J, Qamra A, Irwanto A, Qu Zhengzhong J, Nandi T, Lee-Lim AP, Chan YS, Tay ST, Lee MH, Davies JO, Wong WK, Soo KC, Chan WH, Ong HS, Chow P, Wong CY, **Rha SY**, Liu J, Hillmer AM, Hughes JR, Rozen S, Teh BT, Fullwood MJ, Li S, Tan P. *Nat Commun.* 2016 Sep 28;7:12983. doi: 10.1038/ncomms12983.
57. A novel TP53-KPNA3 translocation defines a de novo treatment-resistant clone in osteosarcoma. Chen KS, Kwon WS, Kim J, Heo SJ, Kim HS, Kim HK, Kim SH, Lee WS, Chung HC, **Rha SY**, Hwang TH. *Cold Spring Harb Mol Case Stud.* 2016 Sep;2(5):a000992. doi: 10.1101/mcs.a000992.
58. High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer. Park JS, Chon HJ, Jeung HC, Shin SJ, **Rha SY**, Ahn JB, Lee KY, Kim NK, Chung HC. *J*

59. A phase II biomarker-embedded study of lapatinib plus capecitabine as first-line therapy in patients with advanced or metastatic gastric cancer. Labonte MJ, Yang D, Zhang W, Wilson PM, Nagarwala YM, Koch KM, Briner C, Kaneko T, **Rha SY**, Gladkov O, Urba SG, Sakaeva D, Pishvaian MJ, Hsieh RK, Lee WP, Lenz HJ. *Mol Cancer Ther.* 2016 Sep;15(9):2251-8.
60. Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial. Pavlakis N, Sjoquist KM, Martin AJ, Tsobanis E, Yip S, Kang YK, Bang YJ, Alcindor T, O'Callaghan CJ, Burnell MJ, Tebbutt NC, **Rha SY**, Lee J, Cho JY, Lipton LR, Wong M, Strickland A, Kim JW, Zalcborg JR, Simes J, Goldstein D. *J Clin Oncol.* 2016 Aug 10;34(23):2728-35.
61. Controlling chemotherapy-induced nausea requires further improvement: symptom experience and risk factors among Korean patients. **Rha SY**, Park Y, Song SK, Lee CE, Lee J. *Support Care Cancer.* 2016 Aug;24(8):3379-89.
62. Rho GTPase RhoJ is Associated with Gastric Cancer Progression and Metastasis. Kim C, Yang H, Park I, Chon HJ, Kim JH, Kwon WS, Lee WS, Kim TS, **Rha SY**. *J Cancer.* 2016 Jul 8;7(11):1550-6.
63. Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. Kim HS, Shin SJ, Beom SH, Jung M, Choi YY, Son T, Kim HI, Cheong JH, Hyung WJ, Noh SH, Chung H, Park JC, Shin SK, Lee SK, Lee YC, Koom WS, Lim JS, Chung HC, **Rha SY**, Kim H. *Oncotarget.* 2016 Jul 12;7(28):44608-44620.
64. Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. Kim C, Kim EK, Jung H, Chon HJ, Han JW, Shin KH, Hu H, Kim KS, Choi YD, Kim S, Lee YH, Suh JS, Ahn JB, Chung HC, Noh SH, **Rha SY**, Kim SH, Kim HS. *BMC Cancer.* 2016 Jul 8;16:434.
65. Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients. Lim SM, Kim YN, Park KH, Kang B, Chon HJ, Kim C, Kim JH, **Rha SY**. *BMC Cancer.* 2016 Jul 4;16(1):385.
66. Fibroblast Growth Factor Receptor 1 Overexpression Is Associated with Poor Survival in Patients with Resected Muscle Invasive Urothelial Carcinoma. Lim S, Koh MJ, Jeong HJ, Cho NH, Choi YD, Cho do Y, Lee HY, **Rha SY**. *Yonsei Med J.* 2016 Jul;57(4):831-9.
67. Prognostic Model to Predict Survival Outcome for Curatively Resected Liposarcoma: A Multi-Institutional Experience. Oh YJ, Yi SY, Kim KH, Cho YJ, Beum SH, Lee YH, Suh JS, Hur H, Kim KS, Kim SH, Choi YD, Shin KH, Jun HJ, Kim SJ, Lee J, Park SH, Noh SH, **Rha SY**, Kim HS. *J Cancer.* 2016 Jun 7;7(9):1174-80.

68. Prognostic significance and frequency of EGFR expression and amplification in surgically resected advanced gastric cancer. Park JS, Kim HS, Bae YS, Cheong JH, **Rha SY**, Noh SH, Kim H. *Jpn J Clin Oncol*. 2016 Jun;46(6):507-16.
69. Assessment of Adrenal Function and Health-Related Quality of Life in Advanced Gastric Cancer Patients Who Received First-Line Chemotherapy. Kim HR, Kim JH, Rhee Y, Lee H, Song SE, Kim C, Song S, Noh SH, **Rha SY**. *Oncology*. 2016 May;90(5):248-54.
70. Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival. Roh MR, Gupta S, Park KH, Chung KY, Lauss M, Flaherty KT, Jönsson G, **Rha SY**, Tsao H. *J Invest Dermatol*. 2016 May;136(5):1002-11.
71. Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma. Lim SM, Kim H, Kang B, Kim HS, **Rha SY**, Noh SH, Hyung WJ, Cheong JH, Kim HI, Chung HC, Yun M, Cho A, Jung M. *Ann Nucl Med*. 2016 May;30(4):279-86.
72. Prognostic implications of PIK3CA amplification in curatively resected liposarcoma. Kim JH, Lee JS, Kim EJ, Park KH, Kim KH, Yi SH, Kim HS, Cho YJ, Shin KH, Ahn JB, Hu H, Kim KS, Choi YD, Kim S, Lee YH, Suh JS, Noh SH, **Rha SY**, Kim HS. *Oncotarget*. 2016 Apr 26;7(17):24549-58.
73. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, **Rha SY**, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR. *Lancet*. 2016 Apr 16;387(10028):1629-37.
74. A Retrospective Analysis for Patients with HER2 Positive Gastric Cancer who were Treated with Trastuzumab-based Chemotherapy: In the Perspectives of Ethnicity and Histology. Yi JH, Kang JH, Hwang IG, Ahn HK, Baek HJ, Lee SI, Lim DH, Won YW, Ji JH, Kim HS, **Rha SY**, Oh SY, Lee KE, Lim T, Maeng CH, Kim MJ, Kim ST, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH. *Cancer Res Treat*. 2016 Apr;48(2):553-60.
75. PTEN Methylation Dependent Sinonasal Mucosal Melanoma. Lee SH, Roh MR, Kang B, Park KH, Kim SH, Lee SE, **Rha SY**. *Cancer Res Treat*. 2016 Apr;48(2):853-8.
76. Craniofacial osteosarcoma: Single institutional experience in Korea. Lim S, Lee S, RhaSY, Rho JK. *Asia Pac J Clin Oncol*. 2016 Mar;12(1):e149-53.

77. Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites. Lim B, Kim C, Kim JH, Kwon WS, Lee WS, Kim JM, Park JY, Kim HS, Park KH, Kim TS, Park JL, Chung HC, **Rha SY**, Kim SY. *Oncotarget*. 2016 Feb 16;7(7):8055-66.
78. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Kaymakalan MD, Xie W, Albiges L, North SA, Kollmannsberger CK, Smoragiewicz M, Kroeger N, Wells JC, **Rha SY**, Lee JL, McKay RR, Fay AP, De Velasco G, Heng DY, Choueiri TK. *Cancer*. 2016 Feb 1;122(3):411-9.
79. Regulation of the epithelial to mesenchymal transition and metastasis by Raf kinase inhibitory protein-dependent Notch1 activity. Noh HS, Hah YS, Ha JH, Kang MY, Zada S, **Rha SY**, Kang SS, Kim HJ, Park JY, Byun JH, Hahm JR, Shin JK, Jeong SH, Lee YJ, Kim DR. *Oncotarget*. 2016 Jan 26;7(4):4632-46.
80. Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference. Baiocchi GL, D'Ugo D, Coit D, Hardwick R, Kassab P, Nashimoto A, Marrelli D, Allum W, Berruti A, Chandramohan SM, Coburn N, González-Moreno S, Hoelscher A, Jansen E, Leja M, Mariette C, Meyer HJ, Mönig S, Morgagni P, Ott K, Preston S, **Rha SY**, Roviello F, Sano T, Sasako M, Shimada H, Schuhmacher C, So Bok-Yan J, Strong V, Yoshikawa T, Terashima M, Ter-Ovanesov M, Van der Velde C, Memo M, Castelli F, Pecorelli S, Detogni C, Kodera Y, de Manzoni G. *Gastric Cancer*. 2016 Jan;19(1):15-20.
81. p16 Hypermethylation and KRAS Mutation are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with mCRC. Kim SH, Park KH, Shin SJ, Lee KY, Kim TI, Kim NK, **Rha SY**, Roh JK, Ahn JB. *Cancer Res Treat*. 2016 Jan;48(1):208-15.
82. Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy. Lee CK, Jung M, Jung I, Heo SJ, Jeong YH, An JY, Kim HI, Cheong JH, Hyung WJ, Noh SH, Kim HS, **Rha SY**, Chung HC. *Ann Surg*. 2016 Jan;263(1):96-102.
83. Leiomyosarcoma: investigation of prognostic factors for risk-stratification model. Kim HJ, Cho YJ, Kim SH, **Rha SY**, Ahn JB, Yang WI, Lee YH, Suh JS, Roh JK, Kim KS, Choi YD, Shin KH, Kim HS. *Int J Clin Oncol*. 2015 Dec;20(6):1226-32.
84. The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer. Chon HJ, Kim HR, Shin E, Kim C, Heo SJ, Lee CK, Park JK, Noh SH, Chung HC, **Rha SY**. *Ann Surg Oncol*. 2015 Nov;22(12):3938-45.
85. Prevalence of human papillomavirus infection and RAS mutation in sporadic keratoacanthoma. Roh MR, Kim JH, Lee SH, Oh SJ, Park KH, Chung KY, **Rha SY**. *Int J Dermatol*. 2015 Nov;54(11):e453-7.

86. Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Lin SJ, Gagnon-Bartsch JA, Tan IB, Earle S, Ruff L, Pettinger K, Ylstra B, van Grieken N, **Rha SY**, Chung HC, Lee JS, Cheong JH, Noh SH, Aoyama T, Miyagi Y, Tsuburaya A, Yoshikawa T, Ajani JA, Boussioutas A, Yeoh KG, Yong WP, So J, Lee J, Kang WK, Kim S, Kameda Y, Arai T, Zur Hausen A, Speed TP, Grabsch HI, Tan P. *Gut*. 2015 Nov;64(11):1721-31.
87. Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients who Failed First-line Therapy Containing Darcabazine. Lee CK, Jung M, Choi HJ, Kim HR, Kim HS, Roh MR, Ahn JB, Chung HC, Heo SJ, **Rha SY**, Shin SJ. *Cancer Res Treat*. 2015 Oct;47(4):781-9.
88. Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer. Satoh T, Lee KH, **Rha SY**, Sasaki Y, Park SH, Komatsu Y, Yasui H, Kim TY, Yamaguchi K, Fuse N, Yamada Y, Ura T, Kim SY, Munakata M, Saitoh S, Nishio K, Morita S, Yamamoto E, Zhang Q, Kim JM, Kim YH, Sakata Y. *Gastric Cancer*. 2015 Oct;18(4):824-32.
89. Low-concentration vemurafenib induces the proliferation and invasion of human HaCaT keratinocytes through mitogen-activated protein kinase pathway activation. Roh MR, Kim JM, Lee SH, Jang HS, Park KH, Chung KY, **Rha SY**. *J Dermatol*. 2015 Sep;42(9):881-8.
90. Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer. Chua C, Tan IB, Yamada Y, **Rha SY**, Yong WP, Ong WS, Tham CK, Ng M, Tai DW, Iwasa S, Lim HY, Choo SP. *Cancer Chemother Pharmacol*. 2015 Aug;76(2):397-408.
91. Caregiving burden and the quality of life of family caregivers of cancer patients: the relationship and correlates. **Rha SY**, Park Y, Song SK, Lee CE, Lee J. *Eur J Oncol Nurs*. 2015 Aug;19(4):376-82.
92. Institutional Board Review for Clinical Investigations on Inflammatory Bowel Diseases: A Single-Center Study. Park S, Noh YH, **Rha SY**, Kim WH, Cheon JH. *Intest Res*. 2015 Jul;13(3):274-81.
93. Upregulated, 7q21-22 amplicon candidate gene SHFM1 confers oncogenic advantage by suppressing p53 function in gastric cancer. Tamilzhalagan S, Muthuswami M, Periasamy J, Lee MH, **Rha SY**, Tan P, Ganesan K. *Cell Signal*. 2015 Jun;27(6):1075-86.
94. hTERT mediates norepinephrine-induced Slug expression and ovarian cancer aggressiveness. Choi MJ, Cho KH, Lee S, Bae YJ, Jeong KJ, **Rha SY**, Choi EJ, Park JH, Kim JM, Lee JS, Mills GB, Lee HY. *Oncogene*. 2015 Jun;34(26):3402-12.

95. PINCH-2 presents functional copy number variation and suppresses migration of colon cancer cells by paracrine activity. Park CH, **Rha SY**, Ahn JB, Shin SJ, Kwon WS, Kim TS, An S, Kim NK, Yang WI, Chung HC. *Int J Cancer*. 2015 May 15;136(10):2273-83.
96. Caregiving burden and health-promoting behaviors among the family caregivers of cancer patients. **Rha SY**, Park Y, Song SK, Lee CE, Lee J. *Eur J Oncol Nurs*. 2015 Apr;19(2):174-81.
97. Characteristics of Long-Term and Short-Term Survivors of Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: Results From the International mRCC Database Consortium. Fay AP, Xie WL, Lee JL, Harshman LC, Bjarnason GA, Knox JJ, Ernst S, Wood L, Vaishamayan UN, Yuasa T, Tan MH, **Rha SY**, Donskov F, Agarwal N, Kollmannsberger CK, North SA, Rini BI, Choueiri TK, Heng DY. *Clin Genitourin Cancer*. 2015 Apr;13(2):150-5.
98. Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium. Kyriakopoulos CE, Chittoria N, Choueiri TK, Kroeger N, Lee JL, Srinivas S, Knox JJ, Bjarnason GA, Ernst SD, Wood LA, Vaishampayan UN, Agarwal N, Pal SK, Kanesvaran R, **Rha SY**, Yuasa T, Donskov F, North SA, Heng DY, Rini BI. *Clin Genitourin Cancer*. 2015 Apr;13(2):e79-85.
99. Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. Yoo KH, Kim HS, Lee SJ, Park SH, Kim SJ, Kim SH, La Choi Y, Shin KH, Cho YJ, Lee J, **Rha SY**. *BMC Cancer*. 2015 Mar 19;15:154.
100. Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer. Kim MS, Lim JS, Hyung WJ, Lee YC, **Rha SY**, Keum KC, Koom WS. *World J Gastroenterol*. 2015 Mar 7;21(9):2711-8.
101. Pain palliation in patients with bone metastases using magnetic resonance-guided focused ultrasound with conformal bone system: a preliminary report. Joo B, Park MS, Lee SH, Choi HJ, Lim ST, **Rha SY**, Rachmilevitch I, Lee YH, Suh JS. *Yonsei Med J*. 2015 Mar;56(2):503-9.
102. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Ko JJ, Xie W, Kroeger N, Lee JL, Rini BI, Knox JJ, Bjarnason GA, Srinivas S, Pal SK, Yuasa T, Smoragiewicz M, Donskov F, Kanesvaran R, Wood L, Ernst DS, Agarwal N, Vaishampayan UN, **Rha SY**, Choueiri TK, Heng DY. *Lancet Oncol*. 2015 Mar;16(3):293-300.
103. Clinicopathological Features and Prognostic Significance of HER2 Expression in Gastric Cancer. Park JS, **Rha SY**, Chung HC, Jung M, Kim KH, Jun HJ, Kim H, An JY, Kim HI, Cheong JH, Hyung WJ, Noh SH, Kim HS. *Oncology*. 2015 Feb;88(3):147-56.

104. Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10. Hong SH, Lee S, Kim HG, Lee HJ, Jung KH, Lee SC, Lee NR, Yun J, Woo IS, Park KH, Kim KH, Kim HY, **Rha SY**, Byun JH. *Gynecol Oncol*. 2015 Feb;136(2):212-7.
105. PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer. Zhang X, Park JS, Park KH, Kim KH, Jung M, Chung HC, **Rha SY**, Kim HS. *Oncology*. 2015 Jan;88(2):76-85.
106. Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and Children. Lim SM, Yoo CJ, Han JW, Cho YJ, Kim SH, Ahn JB, **Rha SY**, Shin SJ, Chung HC, Yang WI, Shin KH, Rho JK, Kim HS. *Cancer Res Treat*. 2015 Jan;47(1):9-17.
107. Proper timing of adjuvant chemotherapy affects survival in patients with stage 2 and 3 gastric cancer. Park HS, Jung M, Kim HS, Kim HI, An JY, Cheong JH, Hyung WJ, Noh SH, Kim YI, Chung HC, **Rha SY**. *Ann Surg Oncol*. 2015 Jan;22(1):224-31.
108. Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer. Lee CK, Lee ME, Lee WS, Kim JM, Park KH, Kim TS, Lee KY, Ahn JB, Chung HC, **Rha SY**. *Am J Cancer Res*. 2014 Dec 15;5(1):72-86.
109. The effect of disintegrin-metalloproteinase ADAM9 in gastric cancer progression. Kim JM, Jeung HC, **Rha SY**, Yu EJ, Kim TS, Shin YK, Zhang X, Park KH, Park SW, Chung HC, Powis G. *Mol Cancer Ther*. 2014 Dec;13(12):3074-85.
110. Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane. Park JS, Jeung HC, **Rha SY**, Ahn JB, Kang B, Chon HJ, Hong MH, Lim S, Yang WI, Nam CM, Chung HC. *Cancer Chemother Pharmacol*. 2014 Oct;74(4):799-808.
111. First-Line Mammalian Target of Rapamycin Inhibition in Metastatic Renal Cell Carcinoma: An Analysis of Practice Patterns From the International Metastatic Renal Cell Carcinoma Database Consortium. Harshman LC, Kroeger N, RhaSY, Donskov F, Wood L, Tantravahi SK, Vaishampayan U, Rini BI, Knox J, North S, Ernst S, Yuasa T, Srinivas S, Pal S, Heng DY, Choueiri TK. *Clin Genitourin Cancer*. 2014 Oct;12(5):335-40.
112. Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Heng DY, Wells JC, Rini BI, Beuselink B, Lee JL, Knox JJ, Bjarnason GA, Pal SK, Kollmannsberger CK, Yuasa T, Srinivas S, Donskov F, Bamias A, Wood LA, Ernst DS, Agarwal N, Vaishampayan UN, RhaSY, Kim JJ, Choueiri TK. *Eur Urol*. 2014 Oct;66(4):704-10.

113. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, Srimuninimit V, Pittman K, Sabbatini R, **Rha SY**, Flaig TW, Page R, Bavbek S, Beck JT, Patel P, Cheung FY, Yadav S, Schiff EM, Wang X, Niolat J, Sellami D, Anak O, Knox JJ. *J Clin Oncol*. 2014 Sep 1;32(25):2765-72.
114. A Population-Based Overview of Sequences of Targeted Therapy in Metastatic Renal Cell Carcinoma. Alimohamed N, Lee JL, Srinivas S, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Vaishampayan UN, Tan MH, RhaSY, Donskov F, Tantravahi S, Kollmannsberger C, North S, Rini BI, Choueiri TK, Heng DY. *Clin Genitourin Cancer*. 2014 Aug;12(4):e127-31.
115. A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. Kang YK, RhaSY, Tassone P, Barriuso J, Yu R, Szado T, Garg A, Bang YJ. *Br J Cancer*. 2014 Aug 12;111(4):660-6.
116. Comparison of Melanoma Subtypes among Korean Patients by Morphologic Features and Ultraviolet Exposure. Jang HS, Kim JH, Park KH, Lee JS, Bae JM, Oh BH, **Rha SY**, Roh MR, Chung KY. *Ann Dermatol*. 2014 Aug;26(4):485-90.
117. High KLF4 level in normal tissue predicts poor survival in colorectal cancer patients. Lee HY, Ahn JB, **Rha SY**, Chung HC, Park KH, Kim TS, Kim NK, Shin SJ. *World J Surg Oncol*. 2014 Jul 24;12:232.
118. Vascular Soft-Tissue Sarcomas: A Prognostic Model from a Retrospective Single-Center Study. Park KS, Kim HS, Cho YJ, **Rha SY**, Ahn JB, Yang WI, Lee YH, Suh JS, Shin KH, Roh JK. *Oncology*. 2014 Jun 7;86(5-6):329-335.
119. Angiogenic factor thymidine phosphorylase associates with angiogenesis and lymphangiogenesis in the intestinal-type gastric cancer. Zhang X, Zheng Z, Shin YK, Kim KY, **Rha SY**, Noh SH, Chung HC, Jeung HC. *Pathology*. 2014 Jun;46(4):316-24.
120. Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. Kroeger N, Choueiri TK, Lee JL, Bjarnason GA, Knox JJ, MacKenzie MJ, Wood L, Srinivas S, Vaishampayan UN, **Rha SY**, Pal SK, Yuasa T, Donskov F, Agarwal N, Tan MH, Bamias A, Kollmannsberger CK, North SA, Rini BI, Heng DY. *Eur Urol*. 2014 Jun;65(6):1086-92.
121. Kaposi's Varicelliform-Like Eruption in a Patient Treated with Everolimus for Metastatic Renal Cell Carcinoma: Report of a Rare Case. Hong S, Kim EH, Cho SB, **Rha SY**. *Case Rep Oncol*. 2014 May 27;7(2):337-42.
122. First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. Ko JJ, Choueiri TK, Rini BI, Lee JL, Kroeger N, Srinivas S, Harshman LC, Knox JJ, Bjarnason GA, MacKenzie

MJ, Wood L, Vaishampayan UN, Agarwal N, Pal SK, Tan MH, **Rha SY**, Yuasa T, Donskov F, Bamias A, Heng DY. Br J Cancer. 2014 Apr 15;110(8):1917-22.

123. Clinical features and treatment of collecting duct carcinoma of the kidney from the Korean cancer study group genitourinary and gynecology cancer committee. Kwon KA, Oh SY, Kim HY, Kim HS, Lee HY, Kim TM, Lim HY, Lee NR, Lee HJ, Hong SH, **Rha SY**. Cancer Res Treat. 2014 Apr;46(2):141-7.
124. The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium. Schutz FA, Xie W, Donskov F, Sircar M, McDermott DF, Rini BI, Agarwal N, Pal SK, Srinivas S, Kollmannsberger C, North SA, Wood LA, Vaishampayan U, Tan MH, Mackenzie MJ, Lee JL, **Rha SY**, Yuasa T, Heng DY, Choueiri TK. Eur Urol. 2014 Apr;65(4):723-30.
125. Tumor perfusion-related parameter of diffusion-weighted magnetic resonance imaging: correlation with histological microvessel density. Lee HJ, **Rha SY**, Chung YE, Shim HS, Kim YJ, Hur J, Hong YJ, Choi BW. Magn Reson Med. 2014 Apr;71(4):1554-8.
126. Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients. Wang Y, Choueiri TK, Lee JL, Tan MH, **Rha SY**, North SA, Kollmannsberger CK, McDermott DF, Heng DY. Br J Cancer. 2014 Mar 18;110(6):1433-7.
127. Ifosfamide-induced Fanconi syndrome with diabetes insipidus. Leem AY, Kim HS, Yoo BW, Kang BD, Kim MH, **Rha SY**, Kim HS. Korean J Intern Med. 2014 Mar;29(2):246-9.
128. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Motzer RJ, Porta C, Vogelzang NJ, Sternberg CN, Szczylik C, Zolnierak J, Kollmannsberger C, **Rha SY**, Bjarnason GA, Melichar B, De Giorgi U, Grünwald V, Davis ID, Lee JL, Esteban E, Urbanowitz G, Cai C, Squires M, Marker M, Shi MM, Escudier B. Lancet Oncol. 2014 Mar;15(3):286-96.
129. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency. Kim KH, Kim HY, Kim HR, Sun JM, Lim HY, Lee HJ, Lee S, Bae WK, **Rha SY**; Korean Cancer Study Group; Genitourinary & Gynecology Cancer Committee. Eur J Cancer. 2014 Mar;50(4):746-52.
130. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. McKay RR, Kroeger N, Xie W, Lee JL, Knox JJ, Bjarnason GA, MacKenzie MJ, Wood L, Srinivas S, Vaishampayan UN, **Rha SY**, Pal SK, Donskov F, Tantravahi SK, Rini BI, Heng DY, Choueiri TK. Eur Urol. 2014 Mar;65(3):577-84.

131. The metalloprotease ADAMTS8 displays antitumor properties through antagonizing EGFR-MEK-ERK signaling and is silenced in carcinomas by CpG methylation. Choi GC, Li J, Wang Y, Li L, Zhong L, Ma B, Su X, Ying J, Xiang T, **Rha SY**, Yu J, Sung JJ, Tsao SW, Chan AT, Tao Q. *Mol Cancer Res*. 2014 Feb;12(2):228-38.
132. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Heng DY, Choueiri TK, Rini BI, Lee J, Yuasa T, Pal SK, Srinivas S, Bjarnason GA, Knox JJ, Mackenzie M, Vaishampayan UN, Tan MH, **Rha SY**, Donskov F, Agarwal N, Kollmannsberger C, North S, Wood LA. *Ann Oncol*. 2014 Jan;25(1):149-54.
133. Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review. Oh WK, McDermott D, Porta C, Levy A, Elaidi R, Scotte F, Hawkins R, Castellano D, Bellmunt J, **Rha SY**, Sun JM, Nathan P, Feinberg BA, Scott J, McDermott R, Ahn JH, Wagstaff J, Chang YH, Ou YC, Donnellan P, Huang CY, McCaffrey J, Chiang PH, Chuang CK, Korves C, Neary MP, Diaz JR, Mehmud F, Duh MS. *Int J Oncol*. 2014 Jan;44(1):5-16.
134. Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study. Lee JS, Lim SM, **Rha SY**, Roh JK, Cho YJ, Shin KH, Yang WI, Kim SH, Kim HS. *J Clin Pathol*. 2014 Jan;67(1):33-9.
135. A case of gingival candidiasis with bone destruction on gastric cancer patient receiving cytotoxic chemotherapy. Lim S, Kil TJ, Kim HR, Han S, **Rha SY**. *Case Rep Oncol Med*. 2014;2014:145394.
136. Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer. Yoo C, Lee J, **Rha SY**, Park KH, Kim TM, Kim YJ, Lee HJ, Lee KH, Ahn JH. *Invest New Drugs*. 2013 Dec;31(6):1602-8.
137. Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients. Kim HR, Park HS, Kwon WS, Lee JH, Tanigawara Y, Lim SM, Kim HS, Shin SJ, Ahn JB, **Rha SY**. *Cancer Chemother Pharmacol*. 2013 Oct;72(4):825-35.
138. Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma. Kim KH, Yoon SH, Lee HJ, Kim HS, Shin SJ, Ahn JB, **Rha SY**. *Cancer Chemother Pharmacol*. 2013 Oct;72(4):853-60.
139. Therapeutic strategies for well-differentiated papillary mesothelioma of the peritoneum. Lee YK, Jun HJ, Nahm JH, Lim TS, Park JS, Ahn JB, **Rha SY**, Chung HC, Oh HE, Song JS, Yang WI, Kim HS. *Jpn J Clin Oncol*. 2013 Oct;43(10):996-1003.
140. The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Al-Marrawi MY, Rini BI,

Harshman LC, Bjarnason G, Wood L, Vaishampayan U, Mackenzie M, Knox JJ, Agarwal N, Al-Harbi H, Kollmannsberger C, Tan MH, **Rha SY**, Donskov FN, North S, Choueiri TK, Heng DY; For the International mRCC Database Consortium. *Target Oncol.* 2013 Sep;8(3):203-9.

141. Changing treatment patterns in elderly patients with resectable colon cancer. Kim GM, Ahn JB, **Rha SY**, Kim HS, Kang B, Kim MW, Choi SY, Roh JK, Chung HC, Kim NK, Shin SJ. *Asia Pac J Clin Oncol.* 2013 Sep;9(3):265-72.
142. Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer. Kim C, Chon HJ, Kang B, Kim K, Jeung HC, Chung HC, Noh SH, **Rha SY**. *BMC Cancer.* 2013 Aug 23;13:394.
143. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the international mRCC database consortium criteria. Kroeger N, Xie W, Lee JL, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Srinivas S, Vaishampayan UN, **Rha SY**, Pal SK, Yuasa T, Donskov F, Agarwal N, Kollmannsberger CK, Tan MH, North SA, Rini BI, Choueiri TK, Heng DY. *Cancer.* 2013 Aug 15;119(16):2999-3006.
144. Application of the Adjuvant! Online Model to Korean Breast Cancer Patients: An Assessment of Prognostic Accuracy and Development of an Alternative Prognostic Tool. Jung M, Choi EH, Nam CM, **Rha SY**, Jeung HC, Lee SH, Yang WI, Roh JK, Chung HC. *Ann Surg Oncol.* 2013 Aug;20(8):2615-24.
145. Defining the target volume for post-operative radiotherapy after D2 dissection in gastric cancer by CT-based vessel-guided delineation. Yoon HI, Chang JS, Lim JS, Noh SH, Hyung WJ, An JY, Lee YC, **Rha SY**, Kim KH, Koom WS. *Radiother Oncol.* 2013 Jul;108(1):72-7.
146. PIK3CA Mutations in Hepatocellular Carcinoma in Korea. Kim H, Park CK, Lee SJ, **Rha SY**, Park KH, Lim HY. *Yonsei Med J.* 2013 Jul;54(4):883-7.
147. The Impact of Cigarette Smoking on the Frequency of and Qualitative Differences in KRAS Mutations in Korean Patients with Lung Adenocarcinoma. Kim HR, Ahn JR, Lee JG, Bang DH, Ha SJ, Hong YK, Kim SM, Nam KC, **Rha SY**, Soo RA, Riely GJ, Kim JH, Cho BC. *Yonsei Med J.* 2013 Jul;54(4):865-74.
148. Pharmacogenomic assessment of outcomes of pemetrexed-treated patients with adenocarcinoma of the lung. Jung M, Lee CH, Park HS, Lee JH, Kang YA, Kim SK, Chang J, Kim DJ, **Rha SY**, Kim JH, Cho BC...
149. Combination of CYP Inhibitor with MEK/ERK Inhibitor Enhances the Inhibitory Effect on ERK in BRAF Mutant Colon Cancer Cells. Lim SM, Hwang JW, Ahn JB, Bae SK, Park CH, Kim KY, **Rha SY**, Chung HC, Roh JK, Shin SJ. *Anticancer Res.* 2013 Jun;33(6):2499-508.

150. Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors. Kim HS, Shin SJ, Kim SC, An S, **Rha SY**, Ahn JB, Cho BC, Choi HJ, Sohn JH, Kim HS, Chung HC, Kim JH, Roh JK, Lee S. Support Care Cancer. 2013 Jun;21(6):1751-9.
151. Estimating the adjuvant chemotherapy effect in elderly stage II and III colon cancer patients in an observational study. Kim KY, Cha IH, Ahn JB, Kim NK, **Rha SY**, Chung HC, Roh JK, Shin SJ. J Surg Oncol. 2013 May;107(6):613-8.
152. Telomerase- and angiogenesis-related gene responses to irradiation in human umbilical vein endothelial cells. Chang H, **Rha SY**, Jeung HC, Park KH, Kim TS, Kim YB, Chung HC. Int J Mol Med. 2013 May;31(5):1202-8.
153. Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma. Koh Y, Lim HY, Ahn JH, Lee JL, **Rha SY**, Kim YJ, Kim TM, Lee SH. Ann Oncol. 2013 Apr;24(4):1026-31.
154. Difference of interferon- α and interferon- β on melanoma growth and lymph node metastasis in mice. Melanoma Res...
155. Increased alternative lengthening of telomere phenotypes of telomerase-negative immortal cells upon trichostatin--a treatment. Jung AR, Yoo JE, Shim YH, Choi YN, Jeung HC, Chung HC, **Rha SY**, Oh BK. Anticancer Res.. 2013 Mar;33(3):821-9.
156. Characterization of naturally Epstein-Barr virus infected gastric carcinoma cell line YCCEL1. Kim DN, Seo MK, Choi H, Kim SY, Shin HJ, Yoon AR, Tao Q, **Rha SY**, Lee SK. J Gen Virol. 2013 Mar;94(Pt 3):497-506.
157. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan MH, **Rha SY**, Agarwal N, Kollmannsberger C, Rini BI, Choueiri TK. Lancet Oncol. 2013 Feb;14(2):141-8.
158. Identifying genes related to radiation resistance in oral squamous cell carcinoma cell lines. Lee SY, Park HR, Cho NH, Choi YP, **Rha SY**, Park SW, Kim SH. Int J Oral Maxillofac Surg. 2013 Feb;42(2):169-76.
159. Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated With Poor Survival and Cigarette Smoking Dosage in Patients With Resected Squamous Cell Lung Cancer. Kim HR, Kim DJ, Kang DR, Lee JG, Lim SM, Lee CY, **Rha SY**, Bae MK, Lee YJ, Kim SH, Ha SJ, Soo RA, Chung KY, Kim JH, Lee JH, Shim HS, Cho BC. J Clin Oncol. 2013 Feb 20;31(6):731-7.

160. Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent. Shin SJ, Hwang JW, Ahn JB, **Rha SY**, Roh JK, Chung HC. Invest New Drugs. 2013 Feb;31(1):1-13.
161. Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program. van den Eertwegh AJ, Karakiewicz P, Bavbek S, **Rha SY**, Bracarda S, Bahl A, Ou YC, Kim D, Panneerselvam A, Anak O, Grünwald V. Urology. 2013 Jan;81(1):143-9.
162. Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. Ivanova T, Zouridis H, Wu Y, Cheng LL, Tan IB, Gopalakrishnan V, Ooi CH, Lee J, Qin L, Wu J, Lee M, **Rha SY**, Huang D, Liem N, Yeoh KG, Yong WP, Teh BT, Tan P. Gut. 2013 Jan;62(1):22-33.
163. Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer. Kim YB, Jeung HC, Jeong I, Lee K, **Rha SY**, Chung HC, Kim GE. J Radiat Res. 2013 Jan;54(1):52-60.
164. Evaluation of survival benefits by platinum and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis. Lee J, Hahn S, Kim DW, Kim J, Kang SN, **Rha SY**, Lee KB, Kang JH, Park BJ. Br J Cancer. 2013 Jan 15;108(1):39-48.
165. Quantitative analysis of ERK signaling inhibition in colon cancer cell lines using phospho-specific flow cytometry. Lim SM, Hwang JW, Bae SK, Bae SH, Ahn JB, **Rha SY**, Roh JK, Chung HC, Shin SJ...
166. EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI. Jung M, Cho BC, Lee CH, Park HS, Kang YA, Kim SK, Chang J, Kim DJ, **Rha SY**, Kim JH, Lee JH. Yonsei Med J. 2012 Nov 1;53(6):1128-35.
167. Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experience. Jung M, Kim GW, Jung I, Ahn JB, Roh JK, **Rha SY**, Chung HC, Kim NK, Kim TI, Shin SJ. BMC Cancer. 2012 Oct 12;12:471.
168. Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy. Jung M, Koo JS, Moon YW, Park BW, Kim SI, Park S, Lee SH, Hong S, **Rha SY**, Chung HC, Kim JH, Sohn J. PLoS One. 2012;7(9):e45127.
169. Patterns of regional recurrence after curative D2 resection for stage III (N3) gastric cancer: implications for postoperative radiotherapy. Chang JS, Lim JS, Noh SH, Hyung WJ, An JY, Lee YC, **Rha SY**, Lee CG, Koom WS. Radiother Oncol. 2012 Sep;104(3):367-73.
170. Phase II Study of the Safety and Efficacy of Temsirolimus in East Asian Patients with Advanced Renal Cell Carcinoma. Sun Y, Rha S, Lee SH, Guo J, Ueda T, Qin S, Naito S, Cincotta M, Tokushige K, Akaza

H. Jpn J ClinOncol. 2012 Sep;42(9):836-44.

171. A new prognostic index model using meta-analysis in early-stage epithelial ovarian cancer. Park HJ, Nam EJ, **Rha SY**, Kim S, Kim SW, Kim JW, Kim YT. GynecolOncol. 2012 Sep;126(3):357-63.
172. Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. Yeo W, Chung HC, Chan SL, Wang LZ, Lim R, Picus J, Boyer M, Mo FK, Koh J, **Rha SY**, Hui EP, Jeung HC, Roh JK, Yu SC, To KF, Tao Q, Ma BB, Chan AW, Tong JH, Erlichman C, Chan AT, Goh BC. J ClinOncol. 2012 Sep 20;30(27):3361-7.
173. Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Harshman LC, Xie W, Bjarnason GA, Knox JJ, Mackenzie M, Wood L, Srinivas S, Vaishampayan UN, Tan MH, **Rha SY**, Donskov F, Agarwal N, Kollmannsberger C, North S, Rini BI, Heng DY, Choueiri TK. Lancet Oncol. 2012 Sep;13(9):927-35.
174. A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDGF) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy. Shin SJ, Jung M, Jeung HC, Kim HR, **Rha SY**, Roh JK, Chung HC, Ahn JB. Invest New Drugs. 2012 Aug;30(4):1501-10.
175. Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells. Kim HS, Kim SC, Kim SJ, Park CH, Jeung HC, Kim YB, Ahn JB, Chung HC, **Rha SY**. BMC Genomics. 2012 Jul 30;13:348.
176. Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea. Ro J, Park S, Kim SB, Kim TY, Im YH, **Rha SY**, Chung JS, Moon H, Santillana S. BMC Cancer. 2012 Jul 28;12(1):322.
177. Methylation Status of Lamin A/C in Gastric Cancer Cell Lines. Lee WS, Jung JJ, Jeung HC, Noh SW, Oh BK, Kim KY, Kim TS, Chung HC, Roh JK, **Rha SY**. Hepatogastroenterology. 2012 Jun;59(116):1313-8.
178. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Zang ZJ, Cutcutache I, Poon SL, Zhang SL, McPherson JR, Tao J, Rajasegaran V, Heng HL, Deng N, Gan A, Lim KH, Ong CK, Huang D, Chin SY, Tan IB, Ng CC, Yu W, Wu Y, Lee M, Wu J, Poh D, Wan WK, **Rha SY**, So J, Salto-Tellez M, Yeoh KG, Wong WK, Zhu YJ, Futreal PA, Pang B, Ruan Y, Hillmer AM, Bertrand D, Nagarajan N, Rozen S, Teh BT, Tan P. Nat Genet. 2012 May;44(5):570-4.

179. Differential expression patterns of MMPs and their role in the invasion of epithelial premalignant tumors and invasive cutaneous squamous cell carcinoma. Roh MR, Zheng Z, Kim HS, Kwon JE, Jeung HC, **Rha SY**, Chung KY. *ExpMolPathol*. 2012 Apr;92(2):236-42.
180. A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. Shin SJ, Ahn JB, Park KS, Lee YJ, Hong YS, Kim TW, Kim HR, **Rha SY**, Roh JK, Kim DH, Kim C, Chung HC. *Invest New Drugs*. 2012 Apr;30(2):672-80.
181. Body fluid MMP-2 as a putative biomarker in metastatic breast cancer. Noh S, Jung JJ, Jung M, Kim KH, Lee HY, Wang B, Cho J, Kim TS, Jeung HC, **Rha SY**. *OncolLett*. 2012 Mar;3(3):699-703.
182. Weekly gemcitabine and docetaxel in refractory soft tissue sarcoma: a retrospective analysis. Lee HY, Shin SJ, Kim HS, Hong SJ, Han JW, Lim ST, Roh JK, **Rha SY**. *Cancer Res Treat*. 2012 Mar;44(1):43-9.
183. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Kim GM, Jeung HC, **Rha SY**, Kim HS, Jung I, Nam BH, Lee KH, Chung HC...
184. Identification of GABRA1 and LAMA2 as new DNA methylation markers in colorectal cancer. Lee S, Oh T, Chung H, Rha S, Kim C, Moon Y, Hoehn BD, Jeong D, Lee S, Kim N, Park C, Yoo M, An S. *Int J Oncol*. 2012 Mar;40(3):889-98.
185. Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma. Lee EM, **Rha SY**, Lee J, Park KH, Ahn JH. *Cancer ChemotherPharmacol*. 2012 Mar;69(3):635-42.
186. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Barrios CH, Hernandez-Barajas D, Brown MP, Lee SH, Fein L, Liu JH, Hariharan S, Martell BA, Yuan J, Bello A, Wang Z, Mundayat R, **Rha SY**. *Cancer*. 2012 Mar 1;118(5):1252-9.
187. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, Zhang S, Lee M, Wu J, Lim KH, Lei Z, Goh G, Lim QY, Lay-Keng Tan A, Sin Poh DY, Riahi S, Bell S, Shi MM, Linnartz R, Zhu F, Yeoh KG, Toh HC, Yong WP, Cheong HC, **Rha SY**, Boussioutas A, Grabsch H, Rozen S, Tan P. *Gut*. 2012 Feb 7.;61(5):673-84.
188. An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. Grünwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin J, Bono P, **Rha SY**, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O,

Rosamilia M, Booth J, Pirotta N, Bodrogi I; on behalf of the REACT Study Group. *Eur J Cancer*. 2012 Feb; 48(3):324-332.

189. External validation of nomogram for the prediction of recurrence after curative resection in early gastric cancer. Kim JH, Kim HS, Seo WY, Nam CM, Kim KY, Jeung HC, Lai JF, Chung HC, Noh SH, **Rha SY**. *Ann Oncol*. 2012 Feb;23(2):361-7.
190. A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer. Lee SS, Jeung HC, Chung HC, Noh SH, Hyung WJ, Ahn JY, **Rha SY**. *Invest New Drugs*. 2012 Feb;30(1):357-63.
191. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Kim HR, Shim HS, Chung JH, Lee YJ, Hong YK, **Rha SY**, Kim SH, Ha SJ, Kim SK, Chung KY, Soo R, Kim JH, Cho BC. *Cancer*. 2012 Feb; 118(3): 729-39.
192. A Densely Interconnected Genome-Wide Network of MicroRNAs and Oncogenic Pathways Revealed Using Gene Expression Signatures. Ooi CH, Oh HK, Wang HZ, Tan AL, Wu J, Lee M, **Rha SY**, Chung HC, Virshup DM, Tan P. *PLoS Genet*. 2011 Dec;7(12):e1002415.
193. Advanced Detection of Recent Changing Trends in Gastric Cancer Survival: Up-to-date Comparison by Period Analysis. Kim HS, Lee H, Jeung HC, Noh SH, Chung HC, Roh JK, Nam CM, **Rha SY**. *Jpn J ClinOncol*. 2011 Dec;41(12):1344-50.
194. Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis. Kim HR, Min BS, Kim JS, Shin SJ, Ahn JB, Rho JK, Kim NK, **Rha SY**. *Oncology*. 2011 Dec;81(3-4):175-83.
195. MMP-2 as a Putative Biomarker for Carcinomatosis in Gastric Cancer. Noh S, Jung JJ, Jung M, Kim TS, Park CH, Lim SJ, Jeung HC, Cheol H, Chung HC, **Rha SY**. *Hepatogastroenterology*. 2011 Nov-Dec;58(112):2015-9.
196. Systematic analyses of genes associated with radiosensitizing effect by celecoxib, a specific cyclooxygenase-2 inhibitor. Kim YM, Shin YK, Jun HJ, **Rha SY**, Pyo H. *J Radiat Res (Tokyo)*. 2011 Nov;52(6):752-65.
197. Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study. Ohtsu A, Shah MA, Van Cutsem E, **Rha SY**, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK. *J ClinOncol*. 2011 Oct 20; 29(30):3968-76.

198. Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer. Chon HJ, **Rha SY**, Park HS, Shin SJ, Kim HS, Roh JK, Noh SH, Chung HC, Jeung HC. *Cancer ChemotherPharmacol*. 2011 Oct;68(4):991-9.
199. Treatment of recurrent hepatocellular carcinoma after liver transplantation. Kim HR, Cheon SH, **Rha SY**, Lee S, Han KH, Chon CY, Lee JD, Sung JS, Chung HC. *Asia Pac J ClinOncol*. 2011 Sep;7(3):258-69.
200. Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer. Jeung HC, **Rha SY**, Shin SJ, Lim SJ, Roh JK, Noh SH, Chung HC. *Anticancer Drugs*. 2011 Sep;22(8):801-10.
201. Sunitinib for asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. Kim HS, Hong MH, Kim K, Shin SJ, Ahn JB, Jeung HC, Chung HC, Koh Y, Lee SH, Bang YJ, **Rha SY** *Oncology*. 2011 Aug;80(5-6):395-405. .
202. Gadoxetate disodium-enhanced hepatobiliary phase MRI of hepatocellular carcinoma: correlation with histological characteristics. Choi JY, Kim MJ, Park YN, Lee JM, Yoo SK, **Rha SY**, Seok JY. *AJR Am J Roentgenol*. 2011 Aug;197(2):399-405.
203. Intrinsic Subtypes of Gastric Cancer, Based on Gene Expression Pattern, Predict Survival and Respond Differently to Chemotherapy. Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, Tan SH, Wu J, Lee MH, Ooi CH, **Rha SY**, Wong WK, Boussioutas A, Yeoh KG, So J, Yong WP, Tsuburaya A, Grabsch H, Toh HC, Rozen S, Cheong JH, Noh SH, Wan WK, Ajani JA, Lee JS, Tellez MS, Tan P. *Gastroenterology*. 2011 Aug;141(2):476-85.
204. Economic and patient-reported outcomes of outpatient home-based versus inpatient hospital-based chemotherapy for patients with colorectal cancer. Joo EH, **Rha SY**, Ahn JB, Kang HY. *Support Care Cancer*. 2011 Jul;19(7):971-8.
205. A Prognostic Model to Predict Clinical Outcome in Gastric Cancer Patients with Bone Metastasis. Park HS, **Rha SY**, Kim HS, Hyung WJ, Park JS, Chung HC, Noh SH, Jeung HC. *Oncology*. 2011 Jun 15;80(1-2):142-150.
206. Comparison of Long-Term Outcome between Doublet and Triplet Neoadjuvant Chemotherapy in Non-Metastatic Osteosarcoma of the Extremity. Hong S, Shin SJ, Jung M, Jeong J, Lee YJ, Shin KH, Roh JK, **Rha SY**. *Oncology*. 2011 Jun 14;80(1-2):107-117.
207. Prevalence and associated factors of psychological distress among Korean cancer patients. Kim SJ, **Rha SY**, Song SK, Namkoong K, Chung HC, Yoon SH, Kim GM, Kim KR. *Gen Hosp Psychiatry*. 2011 May-Jun;33(3):246-52.

208. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy. Jeung HC, **Rha SY**, Im CK, Shin SJ, Ahn JB, Yang WI, Roh JK, Noh SH, Chung HC. *Cancer*. 2011 May 15;117(10):2050-7.
209. Genomic Loss of miR-486 Regulates Tumor Progression and the OLFM4 Antiapoptotic Factor in Gastric Cancer. Oh HK, Tan AL, Das K, Ooi CH, Deng NT, Tan IB, Beillard E, Lee J, Ramnarayanan K, **Rha SY**, Palanisamy N, Voorhoeve PM, Tan P. *Clin Cancer Res*. 2011 May 1;17(9):2657-67.
210. CD44-SLC1A2 Gene Fusions in Gastric Cancer. Tao J, Deng NT, Ramnarayanan K, Huang B, Oh HK, Leong SH, Lim SS, Tan IB, Ooi CH, Wu J, Lee M, Zhang S, **Rha SY**, Chung HC, Smoot DT, Ashktorab H, Kon OL, Cacheux V, Yap C, Palanisamy N, Tan P. *SciTransl Med*. 2011 Apr 6;3(77):77ra30.
211. Genome-wide molecular characterization of mucinous colorectal adenocarcinoma using cDNA microarray analysis. Kim HS, Kang SH, Park CH, Yang WI, Jeung HC, Chung HC, Roh JK, Ahn JB, Kim NK, Min BS, **Rha SY**. *Oncol Rep*. 2011 Mar;25(3):717-27.
212. Brain metastases from colorectal carcinoma: prognostic factors and outcome. Jung M, Ahn JB, Chang JH, Suh CO, Hong S, Roh JK, Shin SJ, **Rha SY**. *J Neurooncol*. 2011 Jan;101(1):49-55.
213. Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells. Chang H, Jeung HC, Jung JJ, Kim TS, **Rha SY**, Chung HC. *Breast Cancer Res Treat*. 2011 Jan;101(1):49-55.
214. Clinicopathologic features of metachronous or synchronous gastric cancer patients with three or more primary sites. Kim JH, **Rha SY**, Kim C, Kim GM, Yoon SH, Kim KH, Kim MJ, Ahn JB, Chung HC, Roh JK, Kim HS. *Cancer Res Treat*. 2010 Dec;42(4):217-24.
215. The Clinical Outcome of Chemotherapy-Induced Amenorrhea in Premenopausal Young Patients with Breast Cancer with Long-Term Follow-up. Jung M, Shin HJ, **Rha SY**, Jeung HC, Hong S, Moon YW, Kim HS, Oh KJ, Yang WI, Roh JK, Chung HC. *Ann SurgOncol*. 2010 Dec;17(12):3259-68.
216. Identification of genes related to a synergistic effect of taxane and suberoylanilidehydroxamic acid combination treatment in gastric cancer cells. Chang H, **Rha SY**, Jeung HC, Jung JJ, Kim TS, Kwon HJ, Kim BS, Chung HC. *J Cancer Res ClinOncol*. 2010 Dec;136(12):1901-13.
217. Chemokine growth-regulated oncogene 1 as a putative biomarker for gastric cancer progression. Jung JJ, Noh S, Jeung HC, Jung M, Kim TS, Noh SH, Roh JK, Chung HC, **Rha SY**. *Cancer Sci*. 2010 Oct;101(10):2200-6.

218. A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer. Shin SJ, Jeung HC, Ahn JB, **Rha SY**, Roh JK, Park KS, Kim DH, Kim C, Chung HC. Invest New Drugs. 2010 Oct;28(5):650-8.
219. Identification of novel gastric cancer-associated CNVs by integrated analysis of microarray. Park CH, **Rha SY**, Jeung HC, Kang SH, Ki DH, Lee WS, Noh SH, Chung HC. J Surg Oncol. 2010 Oct 1;102(5):454-61.
220. Molecular characterization of alternative SET-NUP214 fusion transcripts in a case of acute undifferentiated leukemia. Kim J, Lee SG, Song J, Kim SJ, **Rha SY**, Lee KA, Park TS, Choi JR. Cancer Genet Cytogenet. 2010 Sep;201(2):73-80.
221. Novel sunitinib strategy in metastatic renal cell carcinoma on hemodialysis: intermittent dose of sunitinib after hemodialysis. Yoon SH, Kim KH, Choi J, Kim GM, Kim JH, Kim HS, Park YN, **Rha SY**. Cancer Res Treat. 2010 Sep;42(3):180-4.
222. Kidney Cancer Working Group report. Naito S, Tomita Y, **Rha SY**, Uemura H, Oya M, Song HZ, Zhong LH, Wahid MI. Jpn J Clin Oncol. 2010 Sep;40Suppl 1:i51-56.
223. Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design. Moon YW, **Rha SY**, Jeung HC, Kim C, Hong MH, Chang H, Roh JK, Noh SH, Kim BS, Chung HC. Cancer Chemother Pharmacol. 2010 Sep;66(4):797-805.
224. Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma. HR Kim, SH Cheon, K Lee, JR Ahn, HC Jeung, SS Lee, HC Chung, SH Noh, **Rha SY**. Int J Hyperthermia 2010 June; 26(4):305-315 (2.412).
225. Wernicke's Encephalopathy in Advanced Gastric Cancer. Jung ES, Kwon O, Lee SH, Lee KB, Kim JH, Yoon SH, Kim GM, Jeung HC, **Rha SY**. Cancer Res Treat. 2010 Jun;42(2):77-81.
226. Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer. Shin SJ, Kim NK, Keum KC, Kim HG, Im JS, Choi HJ, Baik SH, Choen JH, Jeung HC, **Rha SY**, Roh JK, Chung HC, Ahn JB. Radiother Oncol. 2010 Jun;95(3):303-7.
227. Green tea consumption and stomach cancer risk: a meta-analysis. Kang H, **Rha SY**, Oh KW, Nam CM. Epidemiol Health. 2010 Apr 26;32:e2010001.
228. The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites. M Jung, HC Jeung, SS Lee, JY Park, S Kong, SH Lee, SH Noh, HC Chung, **Rha SY**. J Cancer Res Clin Oncol. 2010 Apr;136(4):517-26.

229. Adenocarcinoma of the small bowel at a single Korean institute: management and prognosticators. Moon YW, **Rha SY**, Shin SJ, Chang H, Shim HS, Roh JK. *J Cancer Res ClinOncol*. 2010 Mar;136(3):387-94.
230. A Phase II Study of a Combined Biweekly Irinotecan and Monthly Cisplatin Treatment for Metastatic or Recurrent Gastric Cancer. Im CK, **Rha SY**, Jeung HC, Ahn JB, Shin SJ, Noh SH, Roh JK, Chung HC. *Am J ClinOncol*. 2010 Feb;33(1):56-60.
231. Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients. Ahn JB, **Rha SY**, Shin SJ, Jeung HC, Kim TS, Zhang X, Park KH, Noh SH, Roh JK, Chung HC. *Cancer Lett*. 2010 Feb 1;288(1):124-32.
232. Association of the ABCB1 3435C>T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy. Chang H, **Rha SY**, Jeung HC, Im CK, Noh SH, Kim JJ, Chung HC. *Oncol Rep*. 2010 Jan;23(1):271-8.
233. Two Dosages of Oral Fluoropyrimidine S-1 of 35 and 40 mg/m² bid: Comparison of the Pharmacokinetic Profiles in Korean Patients with Advanced Gastric Cancer. Jeung HC, **Rha SY**, Shin SJ, Ahn JB, Noh SH, Roh JK, Chung HC. *Jpn J ClinOncol*. 2010 Jan;40(1):29-35.
234. A phase II feasibility study of weekly paclitaxel in heavily pretreated advanced gastric cancer patients with poor performance status. Im CK, **Rha SY**, Jeung HC, Jeong J, Lee SH, Noh SH, Roh JK, Chung HC. *Oncology*. 2009;77(6):349-57.
235. Docetaxel versus Paclitaxel Combined with 5-FU and Leucovorin in Advanced Gastric Cancer: Combined Analysis of Two Phase II Trials. Chon HJ, **Rha SY**, Im CK, Kim C, Hong MH, Kim HR, An JR, Noh SH, Chung HC, Jeung HC. *Cancer Res Treat*. 2009 Dec;41(4):196-204.
236. Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies. Lin CC, Beeram M, Rowinsky EK, Takimoto CH, Ng CM, Geyer CE Jr, Denis LJ, De Bono JS, Hao D, Tolcher AW, **Rha SY**, Jolivet J, Patnaik A. *Cancer ChemotherPharmacol*. 2009 Dec; 65(1):167-75.
237. Identification of significant regional genetic variations using continuous CNV values in aCGH data. Kim KY, Lee GY, Kim J, Jeung HC, Chung HC, **Rha SY**. *Genomics*. 2009 Nov; 94(5):317-23.
238. Increments of alpha-dystroglycan expression in liver metastasis correlate with poor survival in gastric cancer. Moon YW, **Rha SY**, Zhang X, Jeung HC, Yang WI, Kwon O, Jeong JH, Cheon SH, Yoo NC, Chung HC. *J SurgOncol*. 2009 Nov 1;100(6): 459-65.

239. Oncogenic pathway combinations predict clinical prognosis in gastric cancer. Ooi CH, Ivanova T, Wu J, Lee M, Tan IB, Tao J, Ward L, Koo JH, Gopalakrishnan V, Zhu Y, Cheng LL, Lee J, **Rha SY**, Chung HC, Ganesan K, So J, Soo KC, Lim D, Chan WH, Wong WK, Bowtell D, Yeoh KG, Grabsch H, Boussioutas A, Tan P. *PLoS Genet.* 2009 Oct;5(10):e1000676.
240. Clinical value of ezrin expression in primary osteosarcoma. Kim C, Shin E, Hong S, Chon HJ, Kim HR, Ahn JR, Hong MH, Yang WI, Roh JK, **Rha SY**. *Cancer Res Treat.* 2009 Sep;41(3):138-44.
241. A weighted sample size for microarray datasets that considers the variability of variance and multiplicity. Ki-Yeol Kim¹, Hyun Cheol Chung^{2, 3, 4} and Sun Young Rha. *Journal of Bioscience and Bioengineering* 2009 Sep;108:252-258 ..
242. Prognostic index reflecting genetic alteration related to disease-free time for gastric cancer patient. Kim M, **Rha SY**. *Oncol Rep.* 2009 Aug;22(2):421-31.
243. Subtelomeric DNA methylation and telomere length in human cancer cells. Lee ME, **Rha SY**, Jeung HC, Chung HC, Oh BK. *Cancer Lett.* 2009 Aug 18;281(1):82-91.
244. Phospholipase C delta 1 is a novel 3p22.3 tumor suppressor involved in cytoskeleton organization, with its epigenetic silencing correlated with high-stage gastric cancer. Hu XT, Zhang FB, Fan YC, Shu XS, Wong AH, Zhou W, Shi QL, Tang HM, Fu L, Guan XY, **Rha SY**, Tao Q, He C. *Oncogene.* 2009 Jul 2;28(6):2466-75.
245. Prediction of recurrence of early gastric cancer after curative resection. Lai JF, Kim S, Kim K, Li C, Oh SJ, Hyung WJ, **Rha SY**, Chung HC, Choi SH, Wang LB, Noh SH. *Ann SurgOncol.* 2009 Jul;16(7):1896-902.
246. Prognosis of pN3 Stage Gastric Cancer. Ahn JR, Jung M, Kim C, Hong MH, Chon HJ, Kim HR, Jeung HC, Hyung WJ, Lee SS, Chung HC, Noh SH, **Rha SY**. *Cancer Res Treat.* 2009 Jun;41(2):73-9.
247. Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Hong MH, Kim HS, Kim C, Ahn JR, Chon HJ, Shin SJ, Ahn JB, Chung HC, **Rha SY**. *Cancer Res Treat.* 2009 Jun;41(2):67-72.
248. Benefits of recurrent colonic stent insertion in a patient with advanced gastric cancer with carcinomatosis causing colonic obstruction. Park S, Shin SJ, Ahn JB, Jeung HC, **Rha SY**, Lee SK, Chung HC. *Yonsei Med J.* 2009 Apr 30;50(2):296-9.
249. Clinical features and treatment outcomes of advanced stage primary hepatic angiosarcoma. HR Kim, **Rha SY**, SH Cheon, JK Roh, YN Park, NCYoo, *Annals Oncol* 2009 Apr;20(4):780-7...

250. Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assessment of medical literature of randomized controlled trials. Jeung HC, **Rha SY**, Shin SJ, Ahn JB, Roh JK, Park CH, Noh SH, Chung HC. *Cancer ChemotherPharmacol.* 2009 Apr;63(5):919-27.
251. The effect of spleen-preserving lymphadenectomy on surgical outcomes of locally advanced proximal gastric cancer. Oh SJ, Hyung WJ, Li C, Song J, Kang W, **Rha SY**, Chung HC, Choi SH, Noh SH; *J SurgOncol.* 2009 Apr 1;99(5):275-80..
252. Prediction of high-risk patients by genome-wide copy number alterations from remaining cancer after neoadjuvant chemotherapy and surgery. **Rha SY**, Jeung HC, Seo MY, Kim SC, Yang WI, Moon YW, Chung HC. *Int J Oncol.* 2009 Mar;34(3):837-46.
253. Copy number changes can be a predictor for hemoglobin reduction after S-1 monotherapy in gastric cancer. Jeung HC, **Rha SY**, Park CH, Im CK, Shin SJ, Ahn JB, Noh SH, Roh JK, Chung HC. *Int J Oncol.* 2009 Mar 34(3):787-96.
254. G-T haplotype (2677G>T/A and 3435C>T) of ABCB1 gene polymorphisms is associated with ethnic differences to paclitaxel sensitivity in cancer cells with different gene expression pattern. Kwon WS, **Rha SY**, Jeung HC, Ahn JB, Jung JJ, Noh SH, Chung HC. *Cancer Lett.* 2009 Mar 18; 277(2):155-63.
255. Effect of being overweight on postoperative morbidity and long-term surgical outcomes in proximal gastric carcinoma. Oh SJ, Hyung WJ, Song J, **Rha SY**, Chung HC, Choi SH, Noh SH. *J GastroenterolHepatol.* 2009 Mar;24(3):475-9.
256. DLEC1 is a functional 3p22.3 tumour suppressor silenced by promoter CpG methylation in colon and gastric cancers. Ying J, Poon FF, Yu J, Geng H, Wong AH, Qiu GH, Goh HK, **Rha SY**, Tian L, Chan AT, Sung JJ, Tao Q. *Br J Cancer.* 2009 Feb;100(4):663-9.
257. Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. *Ann Oncol.* Chang H, **Rha SY**, Jeung HC, Im CK, Ahn JB, Kwon WS, Yoo NC, Roh JK, Chung HC. 2009 Feb;20(2):272-7.
258. Promoter methylation of the Wnt/beta-catenin signaling antagonist Dkk-3 is associated with poor survival in gastric cancer. Yu J, Tao Q, Cheng YY, Lee KY, Ng SS, Cheung KF, Tian L, **Rha SY**, Neumann U, Röcken C, Ebert MP, Chan FK, Sung JJ. *Cancer.* 2009 Jan 1;115(1):49-60.
259. In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancer. Jung JJ, Jeung HC, Chung HC, Lee JO, Kim TS, Kim YT, Noh SH, **Rha SY**. *Genomics.* 2009 Jan;93(1):52-61.

260. Cyclooxygenase-2 expression in pretreatment biopsy as a predictor of tumor responses after preoperative chemoradiation in rectal cancer. Min BS, Choi YJ, Pyo HR, Kim H, Seong J, Chung HC, **Rha SY**, Kim NK. Arch Surg. 2008 Nov;143(11):1091-7.
261. Mobilized CD34(+) cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer. Shin SJ, Jeung HC, Ahn JB, **Rha SY**, Yoo NC, Roh JK, Noh SH, Chung HC. Cancer Lett. 2008 Nov 8;270(2):269-76.
262. Angiogenic factor thymidine phosphorylase increases cancer cell invasion activity in patients with gastric adenocarcinoma Yu EJ, Lee Y, **Rha SY**, Kim TS, Chung HC, Oh BK, Yang WI, Noh SH, Jeung HC. Mol Cancer Res. 2008 Oct;6(10):1554-66..
263. OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. Cui Y, Ying Y, van Hasselt A, Ng KM, Yu J, Zhang Q, Jin J, Liu D, Rhim JS, **Rha SY**, Loyo M, Chan AT, Srivastava G, Tsao GS, Sellar GC, Sung JJ, Sidransky D, Tao Q. PLoS ONE. 2008 Aug 20;3(8):e2990.
264. SNPAnalyzer 2.0: a web-based integrated workbench for linkage disequilibrium analysis and association analysis. Yoo J, Lee Y, Kim Y, **Rha SY**, Kim Y. BMC Bioinformatics. 2008 Jun 23;9:290.
265. Improving the prediction accuracy in classification using the combined data sets by ranks of gene expressions. Kim KY, Ki DH, Jeung HC, Chung HC, **Rha SY**. BMC Bioinformatics. 2008 Jun 16;9:283.
266. Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene. Ganesan K, Ivanova T, Wu Y, Rajasegaran V, Wu J, Lee MH, Yu K, **Rha SY**, Chung HC, Ylstra B, Meijer G, Lian KO, Grabsch H, Tan P. Cancer Res. 2008 Jun 1;68(11):4277-86.
267. Variation of the 3' telomeric overhang lengths in human cells. Lee ME, **Rha SY**, Jeung HC, Kim TS, Chung HC, Oh BK. Cancer Lett. 2008 Jun 8;264(1):107-118.
268. Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer. Choi HJ, Kim NK, Keum KC, Cheon SH, Shin SJ, Baik SH, Choen JH, **Rha SY**, Roh JK, Jeung HC, Chung HC, Ahn JB. RadiotherOncol. 2008 Jun;87(3):361-6.
269. Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. Cheon SH, **Rha SY**, Jeung HC, Im CK, Kim SH, Kim HR, Ahn JB, Roh JK, Noh SH, Chung HC. Ann Oncol. 2008 Jun;19(6):1146-53.
270. Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer. J Jeong, HC Jeung, **Rha SY**, CK Im, SJ Shin, JB

Ahn, SH Noh, JK Roh and HC Chung. Ann Oncol. 2008 Jun;19(6):1135-40.

271. S-1 monotherapy as a neoadjuvant treatment for locally advanced gastric cancer. Jung JY, **Rha SY**, Ahn JB, Yang WI, Noh SH, Chung HC, Jeung HC. Korean J Intern Med. 2008 Mar;23(1):37-41.
272. Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylicpolyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up. Jeung HC, Moon YW, **Rha SY**, Yoo NC, Roh JK, Noh SH, Min JS, Kim BS, Chung HC. Ann Oncol. 2008 Mar;19(3):520-6.
273. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Lee KS, Chung HC, Im SA, Park YH, Kim CS, Kim SB, **Rha SY**, Lee MY, Ro J. Breast Cancer Res Treat. 2008 Mar;108(2):241-50.
274. A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer. CK Im, HC Jeung, **Rha SY**, NC Yoo, SH Noh, JK Roh, HC Chung, Cancer ChemotherPharmacol 2008 Feb;61(2):315-21...
275. Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer. Shin SJ, Jeung HC, Ahn JB, Choi HJ, Cho BC, **Rha SY**, Yoo NC, Roh JK, Chung HC. Cancer ChemotherPharmacol. 2008 Jan;61(1):157-65.
276. Direct integration of microarrays for selecting informative genes and phenotype classification Y Yoon, J Lee, S Park, S Bien, HC Chung, **Rha SY**. Information Sciences 2008 Jan:178: 88-105...
277. Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma. Yoon KT, Kim JK, Kim Do Y, Ahn SH, Lee JD, Yun M, **Rha SY**, Chon CY, Han KH. Oncology. 2007 Dec;72Suppl 1:104-10.
278. Entropy-based analysis of non-linear relationship between gene expression profiles of amplified and non-amplified RNA. JH Shin, CH Park, YJ Yang, SC Kim, MY Seo, SH Yang, SB Cho, HC Chung, **Rha SY**. Int J Mol Med 2007 Dec;20(6):905-12..
279. Whole genome analysis for liver metastasis gene signatures in colorectal cancer. DH Ki, HC Jeung, CH Park, SH Kang, GY Lee, WS Lee, NK Kim, HC Chung, **Rha SY**. Int J Cancer 2007 Nov 1: 121 (9) 2005-12..
280. Changing Patterns of Prognosticators During 15-Year Follow-Up of Advanced Gastric Cancer after Radical Gastrectomy and Adjuvant Chemotherapy: A 15-Year Follow-Up Study at a Single Korean Institute. Moon YW, Jeung HC, **Rha SY**, Yoo NC, Roh JK, Noh SH, Kim BS, Chung HC. Ann

SurgOncol. 2007 Oct; 14(10):2730-7.

281. Genome-wide genetic aberrations of thymoma using cDNA microarray based comparative genomic hybridization. GY Lee, WI Yang, HC Jeung, SC Kim, MY Seo, CH Park, HC Chung, **Rha SY**. BMC Genomics 2007 Sep 3; 8(1):305..
282. Putative chemosensitivity predictive genes in colorectal cancer cell lines for anticancer agents. JJ Jung, HC Jeung, JO Lee, TS Kim, HC Chung, **Rha SY**. Oncology Reports 2007 Sep; 18(3):593-599 ..
283. Molecular basis of the differences between normal and tumor tissues of gastric cancer. Yang S, Shin J, Park KH, Jeung HC, **Rha SY**, Noh SH, Yang WI, Chung HC. Biochim Biophys Acta. 2007 Sep; 1772(9):1033-40.
284. A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status. Jeung HC, **Rha SY**, Shin SJ, Ahn JB, Noh SH, Roh JK, Chung HC. Br J Cancer. 2007 Aug 20; 97(4):458-63.
285. Different criteria for HER2 positivity by IHC can be applied in post-chemotherapy specimens in determining HER2 as a prognosticator in locally advanced breast cancer. Moon YW, Jeung HC, **Rha SY**, Choi YH, Yang WI, Chung HC. Breast Cancer Res Treat. 2007 Jul;104(1):31-7.
286. Bilateral Breast Cancer: Differential Diagnosis Using Histological and Biological Parameters. Gong SJ, **Rha SY**, Jeung HC, Roh JK, Yang WI, Chung HC. Jpn J Clin Oncol. 2007 Jul; 37(7):487-92.
287. An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients. **Rha SY**, Jeung HC, Choi YH, Yang WI, Yoo JH, Kim BS, Roh JK, Chung HC. Oncologist. 2007 Jun;12(6):622-30.
288. Novel and simple transformation algorithm for combining microarray data sets. Kim KY, Ki DH, Jeong HJ, Jeung HC, Chung HC, **Rha SY**. BMC Bioinformatics. 2007 Jun 25;8:218.
289. Integrated in silico and biological validation of the blocking effect of Cot-1 DNA on Microarray-CGH. Kang SH, Park CH, Jeung HC, Kim KY, **Rha SY**, Chung HC. Int J Mol Med. 2007 Jun;19(6):901-8.
290. Gastrointestinal stromal tumor of the rectum: an analysis of seven cases. Baik SH, Kim NK, Lee CH, Lee KY, Sohn SK, Cho CH, Kim H, Pyo HR, **Rha SY**, Chung HC. Surg Today. 2007 May;37(6):455-9.

291. Multi-Institutional Phase II Study of S-1 Monotherapy in Advanced Gastric Cancer with Pharmacokinetic and Pharmacogenomic Evaluations. Jeung HC, **Rha SY**, Kim HK, Lim HY, Kim S, Kim SY, Gong SJ, Park CH, Ahn JB, Noh SH, Chung HC. *Oncologist*. 2007 May;12(5):543-54.
292. Cetuximab rescue a patient with non-small cell lung cancer from rapid disease progression during chemotherapy. Shin SJ, Lee HW, Kim SH, Ahn JB, Choi HJ, Cho BC, Jeung HC, **Rha SY**, Chung HC, Pyo JY, Roh JK. *ActaOncol*. 2007;46(4):547-9.
293. The tumor suppressor Wnt inhibitory factor 1 is frequently methylated in nasopharyngeal and esophageal carcinomas. Chan SL, Cui Y, van Hasselt A, Li H, Srivastava G, Jin H, Ng KM, Wang Y, Lee KY, Tsao GS, Zhong S, Robertson KD, **Rha SY**, Chan AT, Tao Q. *Lab Invest*. 2007, 87(7):644-50.
294. Identification of genes with correlated patterns of variations in DNA copy number and gene expression level in gastric cancer. Yang S, Jeung HC, Jeong HJ, Choi YH, Kim JE, Jung JJ, **Rha SY**, Yang WI, Chung HC. *Genomics*. 2007 Apr;89(4):451-9.
295. Clinical role of bone marrow angiogenesis in childhood acute lymphocytic leukemia. Lyu CJ, **Rha SY**, Won SC. *Yonsei Med J*. 2007 Apr 30;48(2):171-5.
296. The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. Shin SJ, Ahn JB, Choi HJ, Cho BC, Jeung HC, **Rha SY**, Chung HC, Roh JK. *Cancer ChemotherPharmacol*. 2007 Mar 21.
297. Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: A 15-year experience at a single institute. Cho BC, Jeung HC, Choi HJ, **Rha SY**, Hyung WJ, Cheong JH, Noh SH, Chung HC. *J SurgOncol*. 2007; 95(6):461-8.
298. A comparative study of volumetric analysis, histopathologic downstaging, and tumor regression grade in evaluating tumor response in locally advanced rectal cancer following preoperative chemoradiation. Kim NK, Baik SH, Min BS, Pyo HR, Choi YJ, Kim H, Seong J, Keum KC, **Rha SY**, Chung HC. *Int J RadiatOncolBiol Phys*. 2007;67:204-10.
299. The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. Seng TJ, Low JS, Li H, Cui Y, Goh HK, Wong ML, Srivastava G, Sidransky D, Califano J, Steenbergen RD, **Rha SY**, Tan J, Hsieh WS, Ambinder RF, Lin X, Chan AT, Tao Q. *Oncogene*. 2007 8;26(6):934-44.
300. A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer. Jeung HC, **Rha SY**, Noh SH, Roh JK, Chung HC. *Cancer ChemotherPharmacol*. 2007;59:313 .

301. Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG). Yeo W, Boyer M, Chung HC, Ong SY, Lim R, Zee B, Ma B, Lam KC, Mo FK, Ng EK, Ho R, Clarke S, Roh JK, Beale P, **Rha SY**, Jeung HC, Soo R, Goh BC, Chan AT. *Cancer ChemotherPharmacol.* 2007 Feb;59(3):295-300.
302. A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens. Jeung HC, **Rha SY**, Cho BC, Yoo NC, Roh JK, Roh WJ, Chung HC, Ahn JB. *British J Cancer* 2006 :95:1637-41.
303. Activation of Hypoxia-Inducible Factor-1{alpha} is necessary for Lysophosphatidic Acid-induced VEGF expression. Lee J, Park SY, Lee EK, Park CG, Chung HC, **Rha SY**, Kim YK, Bae GU, Kim BK, Han JW, Lee HY. *Clin Cancer Res.* 2006 Nov 1;12(21):6351-8.
304. Induction of cell apoptosis in non-small cell lung cancer cells by cyclin A1 small interfering RNA. Cho NH, Choi YP, Moon DS, Kim H, Kang S, Ding O, **Rha SY**, Yang YJ, Cho SH. *Cancer Science* 2006;97(10):1082-92 .
305. Ribonucleotidereductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Kwon WS, **Rha SY**, Choi YH, Lee JO, Park KH, Jung JJ, Kim TS, Jeung HC, Chung HC. *Pharmacogenet Genomics.* 2006 Jun;16(6):429-38.
306. Alteration of hTERT full-length variant expression level showed different gene expression profiles and genomic copy number changes in breast cancer. **Rha SY**, Jeung HC, Yang WI, Kim JJ, Oh TJ, An SW, Chung HC. *Oncol Rep.* 2006 Apr;15(4):749-55.
307. Systematic analysis of cDNA microarray-based CGH. Park CH , Jeong HJ , Choi YH , Kim SC , Jeong HC , Park KH , Lee GY , Kim TS, Yang SW, Ahn SW, Kim YS, **Rha SY**, Chung HC. *Int J Mol Med.* 2006 Feb;17(2):261-7.
308. Intermediate dose 5-Fluorouracil-induced encephalopathy. Kim YA, Chung HC, Choi HJ, **Rha SY**, Seong JS, Jeung HC. *Jpn J ClinOncol.* 2006 Jan;36(1):55-9.
309. A Phase II Study of Infusional 5-Fluorouracil and Low-Dose Leucovorin with Docetaxel for Advanced Gastric Cancer. Jeung HC, **Rha SY**, Kim YT, Noh SH, Roh JK, Chung HC. *Oncology.* 2006 Jan 27;70(1):63-70.
310. Quantitative detection of telomerase activity by real-time TRAP assay in the body fluids of cancer patients. Shim WY, Park KH, Jeung HC, Kim YT, Kim TS, Hyung WJ, An SH, Yang SH, Noh SH, Chung HC, **Rha SY**. *Int J Mol Med.* 2005 Nov;16(5):857-63.
311. Cyclic induction of senescence with intermittent AZT treatment accelerates both apoptosis and telomere loss. Ji HJ, **Rha SY**, Jeung HC, Yang SH, An SW, Chung HC. *Breast Cancer Res Treat.* 2005

Oct;93(3):227-36.

312. Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis. Moon YW, **Rha SY**, Jeung HC, Yang WI, Suh CO, Chung HC. *Ann Oncol*. 2005 Nov;16(11):1778-85. Epub 2005 Aug 9.
313. Thymidine phosphorylase suppresses apoptosis induced by microtubule-interfering agents. Jeung HC, Che XF, Haraguchi M, Furukawa T, Zheng CL, Sumizawa T, **Rha SY**, Roh JK, Akiyama S. *Biochem Pharmacol*. 2005 Jul 1;70(1):13-21.
314. Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. **Rha SY**, Moon YH, Jeung HC, Kim YT, Sohn JH, Yang WI, Suh CO, Kim GE, Roh JK, Chung HC. *Breast Cancer Res Treat*. 2005 Apr;90(3):215-21.
315. Gene copy number change events at chromosome 20 and their association with recurrence in gastric cancer patients. Yang SH, Seo MY, Jeong HJ, Jeung HC, Shin J, Kim SC, Noh SH, Chung HC, **Rha SY**. *Clin Cancer Res*. 2005 Jan 15;11(2 Pt 1):612-20.
316. Determination of genes related to gastrointestinal tract origin cancer cells using a cDNA microarray. Kim TM, Jeong HJ, Seo MY, Kim SC, Cho G, Park CH, Kim TS, Park KH, Chung HC, **Rha SY**. *Clin Cancer Res*. 2005 Jan 1;11(1):79-86.
317. Different role of functional domains of hTR in DNA binding to telomere and telomerase reconstruction. Yeo M, **Rha SY**, Jeung HC, Shen XH, Yang SH, An SW, Roh JK, Chung HC. *FEBS Lett*. 2005 Jan 3;579(1):127-32.
318. Attenuation of telomerase activity by hammerhead ribozyme targeting human telomerase RNA induces growth retardation and apoptosis in human breast tumor cells. Yeo M, **Rha SY**, Jeung HC, Hu SX, Yang SH, Kim YS, An SW, Chung HC.
319. Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. de Bono JS, **Rha SY**, Stephenson J, Schultes BC, Monroe P, Eckhardt GS, Hammond LA, Whiteside TL, Nicodemus CF, Cermak JM, Rowinsky EK, Tolcher AW. *Ann Oncol*. 2004 Dec;15(12):1825-33.
320. Statistical methods of translating microarray data into clinically relevant diagnostic information in colorectal cancer. Kim BS, Kim I, Lee S, Kim S, **Rha SY**, Chung HC. *Bioinformatics*. 2005 Feb 15;21(4):517-28. Epub 2004 Sep 16.
321. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. Gong SJ, Jin CJ, **Rha SY**, Chung HC. *Cancer Lett*. 2004 Oct 28;214(2):215-24.
322. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies. Chu QS, Hammond LA, Schwartz G, Ochoa L, **Rha SY**, Denis L, Molpus K, Roedig B, Letrent SP, Damle B, DeCillis AP, Rowinsky EK. *Clin Cancer Res*. 2004 Aug 1;10(15):4913-21.
323. Spearman's footrule as a measure of cDNA microarray reproducibility. Kim BS, **Rha SY**, Cho GB, Chung HC. *Genomics*. 2004 Aug;84(2):441-8.

324. Lack of correlation between P-glycoprotein and chemotherapy resistance in nasal NK/T-cell lymphomas. Kim GE, Yang WI, Lee SW, **Rha SY**, Chung HC, Kim JH, Cho JH, Suh CO, Yoo NC, Roh JK, Hahn JS. *Leuk Lymphoma*. 2004 Sep;45(9):1857-64.
325. Fabrication of high quality cDNA microarray using a small amount of cDNA. Park CH, Jeong HJ, Jung JJ, Lee GY, Kim SC, Kim TS, Yang SH, Chung HC, **Rha SY**. *Int J Mol Med*. 2004 May;13(5):675-9.
326. Expression of matrix metalloproteinase-2 and -9 and tissue inhibitor of metalloproteinase-1 and -2 in intraductal and nonintraductal growth type of cholangiocarcinoma. Jo Chae K, **Rha SY**, Oh BK, Koo JS, Kim YJ, Choi J, Park C, Park YN. *Am J Gastroenterol*. 2004 Jan;99(1):68-75.
327. The pattern of gene copy number changes in bilateral breast cancer surveyed by cDNA microarray-based comparative genomic hybridization. Seo MY, **Rha SY**, Yang SH, Kim SC, Lee GY, Park CH, Yang WI, Ahn JB, Park BW, Chung HC. *Int J Mol Med*. 2004 Jan;13(1):17-24.
328. cDNA Microarray Experiment: Design Issues in Early Stage and the Need of Normalization. Kim BS, Lee S, **Rha SY**, Chung HC. *Cancer Res Treat*. 2003 Dec;35(6):533-40. doi: 10.4143/crt.2003.35.6.533.
329. Increased expression of matrix metalloproteinase 9 correlates with poor prognostic variables in renal cell carcinoma. Cho NH, Shim HS, **Rha SY**, Kang SH, Hong SH, Choi YD, Hong SJ, Cho SH. *Eur Urol*. 2003 Nov;44(5):560-6.
330. A case of paraneoplastic nephrotic syndrome in a patient with ovarian carcinoma. Kim YT, **Rha SY**, Shim CY, Sohn JH, Kim C, Yu NC, Chung HC, Kim JH, Han DS, Kim BS, Roh JK. *Yonsei Med J*. 2003 Jun 30;44(3):539-43. Review.
331. Regions of allelic imbalance in the distal portion of chromosome 12q in gastric cancer. Schneider BG, **Rha SY**, Chung HC, Bravo JC, Mera R, Torres JC, Plaisance KT Jr, Schlegel R, McBride CM, Reveles XT, Leach RJ. *Mol Pathol*. 2003 Jun;56(3):141-9.
332. Paclitaxel and Cisplatin Combination Chemotherapy in Pretreated Breast Cancer. Sohn JH, Kim YT, **Rha SY**, Yoo NC, Roh JK, Kim BS, Suh CO, Kim GE, Jang WI, Chung HC. *Cancer Res Treat*. 2003 Jun;35(3):267-73. doi: 10.4143/crt.2003.35.3.267.
333. Infusional fluorouracil, etoposide, and cisplatin (FEP) in advanced and relapsed gastric cancer. Sohn JH, Jeung HC, Shin HJ, **Rha SY**, Roh JK, Noh SH, Min JS, Kim BS, Jang WI, Chung HC. *Am J Clin Oncol*. 2003 Apr;26(2):203-9.
334. Infusional 5-Fluorouracil, Leucovorin and Docetaxel in Advanced Gastric Cancer. Kim YT, Sohn JH, Kim SH, **Rha SY**, Kim C, Roh JK, Kim BS, Jang WI, Chung HC. *Cancer Res Treat*. 2003 Apr;35(2):123-9. doi: 10.4143/crt.2003.35.2.123.
335. Genome-scale analysis of resveratrol-induced gene expression profile in human ovarian cancer cells using a cDNA microarray. Yang SH, Kim JS, Oh TJ, Kim MS, Lee SW, Woo SK, Cho HS, Choi YH, Kim YH, **Rha SY**, Chung HC, An SW. *Int J Oncol*. 2003 Apr;22(4):741-50.
336. Microarray-based analysis of anti-angiogenic activity of demethoxycurcumin on human umbilical vein endothelial cells: crucial involvement of the down-regulation of matrix metalloproteinase. Kim JH, Shim JS, Lee SK, Kim KW, **Rha SY**, Chung HC, Kwon HJ. *Jpn J Cancer Res*. 2002 Dec;93(12):1378-85.

337. Design and synthesis of fluoroquinophenoxazines that interact with human telomeric G-quadruplexes and their biological effects. Duan W, Rangan A, Vankayalapati H, Kim MY, Zeng Q, Sun D, Han H, Fedoroff OY, Nishioka D, **Rha SY**, Izbicka E, Von Hoff DD, Hurley LH. *Mol Cancer Ther.* 2001 Dec;1(2):103-20.
338. Biological phenotype determination with ex vivo model in gastric cancer for matrix-metalloproteinase inhibitor treatment. **Rha SY**, Jeung HC, Roh JK, Kim JJ, Noh SH, Min JS, Kim BS, Chung HC. *Int J Mol Med.* 2002 Sep;10(3):251-6.
339. A Phase II Study of Gemcitabine Monotherapy in Breast Cancer Patients Refractory to Anthracycline and Taxane. Park JY, Kim C, Sohn JH, Kim YT, **Rha SY**, Jang WI, Kim GE, Chung HC. *Cancer Res Treat.* 2002 Aug;34(4):274-9. doi: 10.4143/crt.2002.34.4.274.
340. Changes of Telomerase Activity and Proliferation by Inhibition of Reverse Transcriptase Activity in Human Cancer Cell. Ji HJ, Park KH, Kim TS, **Rha SY**, Yoo NC, Kim JM, Kim JS, Roh JK, Jang WI, Chung HC. *Cancer Res Treat.* 2002 Jun;34(3):223-33. doi: 10.4143/crt.2002.34.3.223.
341. Treatment of advanced gastric cancer by palliative gastrectomy, cytoreductive therapy and postoperative intraperitoneal chemotherapy. Jeung HC, **Rha SY**, Jang WI, Noh SH, Chung HC. *Br J Surg.* 2002 Apr;89(4):460-6.
342. Efficacy of Pre- and Postoperative Chemotherapy in Patients with Osteosarcoma of the Extremities. Sohn JH, **Rha SY**, Jeung HC, Shin HJ, Goo YS, Chung HC, Yang WI, Hahn SB, Shin KH, Min JS, Kim BS, Roh JK, Jang WI. *Cancer Res Treat.* 2001 Dec;33(6):520-6. doi: 10.4143/crt.2001.33.6.520.
343. Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma: 15-year experience at a single institute. Jeung HC, **Rha SY**, Noh SH, Min JS, Kim BS, Chung HC. *Cancer.* 2001 Jun 1;91(11):2016-25.
344. Monthly 5-days 5-fluorouracil and low-dose leucovorin for adjuvant chemotherapy in colon cancer. Ahn JB, Shim KY, Jeung HC, **Rha SY**, Yoo NC, Kim NK, Roh JK, Min JS, Kim BS, Chung HC. *Cancer Lett.* 2001 Jun 26;167(2):215-24.
345. Tissue urokinase-type plasminogen activator receptor levels in breast cancer. Gong SJ, **Rha SY**, Chung HC, Yoo NC, Roh JK, Yang WI, Lee KS, Min JS, Kim BS, Chung HC. *Int J Mol Med.* 2000 Sep;6(3):301-5.
346. Effect of telomere and telomerase interactive agents on human tumor and normal cell lines. **Rha SY**, Izbicka E, Lawrence R, Davidson K, Sun D, Moyer MP, Roodman GD, Hurley L, Von Hoff D. *Clin Cancer Res.* 2000 Mar;6(3):987-93.
347. Correlation of tissue and blood plasminogen activation system in breast cancer. **Rha SY**, Yang WI, Gong SJ, Kim JJ, Yoo NC, Roh JK, Min JS, Lee KS, Kim BS, Chung HC. *Cancer Lett.* 2000 Mar 31;150(2):137-45."
348. Changes of telomerase and telomere lengths in paired normal and cancer tissues of breast. **Rha SY**, Park KH, Kim TS, Yoo NC, Yang WI, Roh JK, Min JS, Lee KS, Kim BS, Choi JH, Lim HY, Chung HC. *Int J Oncol.* 1999 Oct;15(4):839-45.

349. Modulation of biological phenotypes for tumor growth and metastasis by target-specific biological inhibitors in gastric cancer. **Rha SY**, Noh SH, Kim TS, Yoo NC, Roh JK, Min JS, Kim BS. *Int J Mol Med*. 1999 Aug;4(2):203-12.
350. "Combined pre-operative chemotherapy with intra-arterial cisplatin and continuous intravenous adriamycin for high grade osteosarcoma. **Rha SY**, Chung HC, Gong SJ, Shim KY, Ahn JB, Yang WI, Shin KH, Yoo NC, Kim JH, Roh JK, Lee CI, Kim BS. *Oncol Rep*. 1999 May-Jun;6(3):631-7."
351. Effects of interleukin-2 transduction on the human hepatoma cell lines using retroviral vector. Kim JH, Gong SJ, Yoo NC, Lee H, Shin DH, Uhm HD, Jeong SJ, Cho JY, **Rha SY**, Kim YS, Chung HC, Roh JK, Min JS, Kim BS. *Oncol Rep*. 1999 Jan-Feb;6(1):49-54.
352. Menstrual state should be considered in determining sero-positivity of soluble angiogenic factors in breast cancer. Chung HC, **Rha SY**, Ahn JB, Shim KY, Yoo NC, Kim JH, Roh JK, Lee KS, Min JS, Kim BS, Kim JJ. *Int J Mol Med*. 1998 Oct;2(4):465-70.
353. An unusual case of gastric carcinoma with synchronous non-Hodgkin's lymphoma. Park SH, **Rha SY**, Shim DK, Rho HJ, Yoo NC, Kim JH, Roh JK, Yang WI, Noh SH, Min JS, Kim BS, Chung HC. *Yonsei Med J*. 1998 Oct;39(5):463-7.
354. Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients. Chung HC, **Rha SY**, Park JO, Yoo NC, Kim JH, Roh JK, Min JS, Lee KS, Kim BS, Kim JJ. *Breast Cancer Res Treat*. 1998 May;49(1):41-50.
355. Alpha-fetoprotein-producing gastric cancer. Lee R, **Rha SY**, Ahn JB, Shim KY, Choi JH, Lim HY, Yoo NC, Noh SH, Kim JH, Roh JK, Min JS, Kim BS, Chung HC. *Oncol Rep*. 1998 Sep-Oct;5(5):1179-84.
356. "Telomerase activity and telomere lengths in various cell lines: changes of telomerase activity can be another method for chemosensitivity evaluation. Park KH, **Rha SY**, Kim CH, Kim TS, Yoo NC, Kim JH, Roh JK, Noh SH, Min JS, Lee KS, Kim BS, Chung HC. *Int J Oncol*. 1998 Sep;13(3):489-95."
357. Phase I clinical trial: pharmacokinetics of a novel anthracycline, DA-125 and metabolites. Single dose study. Roh JK, **Rha SY**, Lee CI, Lee KH, Lee JJ, Shim HJ, Lee SD, Kim WB, Yang J, Kim SH, Lee MG. *Int J Clin Pharmacol Ther*. 1998 Jun;36(6):312-9.
358. Different expression patterns of MMP-2 and MMP-9 in breast cancer. **Rha SY**, Yang WI, Kim JH, Roh JK, Min JS, Lee KS, Kim BS, Chung HC. *Oncol Rep*. 1998 Jul-Aug;5(4):875-9.
359. Synchronous elevation of soluble intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) correlates with gastric cancer progression. Yoo NC, Chung HC, Chung HC, Park JO, **Rha SY**, Kim JH, Roh JK, Min JS, Kim BS, Noh SH. *Yonsei Med J*. 1998 Feb;39(1):27-36.
360. A comparative study of intravenous granisetron versus intravenous and oral ondansetron in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy. Park JO, **Rha SY**, Yoo NC, Kim JH, Roh JK, Min JS, Kim BS, Chung HC. *Am J Clin Oncol*. 1997 Dec;20(6):569-72.
361. Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer. Park JO,

Chung HC, Cho JY, **Rha SY**, You NC, Kim JH, Noh SH, Kim CB, Min JS, Kim BS, Roh JK. Am J Clin Oncol. 1997 Oct;20(5):484-9.

362. Comparison of biological phenotypes according to midkine expression in gastric cancer cells and their autocrine activities could be modulated by pentosan polysulfate. **Rha SY**, Noh SH, Kwak HJ, Wellstein A, Kim JH, Roh JK, Min JS, Kim BS, Chung HC. Cancer Lett. 1997 Sep 16;118(1):37-46.
363. Sequential production and activation of matrix-metalloproteinase-9 (MMP-9) with breast cancer progression. **Rha SY**, Kim JH, Roh JK, Lee KS, Min JS, Kim BS, Chung HC.
364. Relationship between p53 overexpression and gastric cancer progression. Kim JH, Uhm HD, Gong SJ, Shin DH, Choi JH, Lee HR, Noh SH, Kim BS, Cho JY, **Rha SY**, Yoo NC, Chung HC, Roh JK, Min JS, Lee KS, Kim BS. Oncology. 1997 Mar-Apr;54(2):166-70.
365. P-glycoprotein: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. Chung HC, **Rha SY**, Kim JH, Roh JK, Min JS, Lee KS, Kim BS, Lee KB. Breast Cancer Res Treat. 1997 Jan;42(1):65-72.
366. Sequential activation and production of matrix metalloproteinase-2 during breast cancer progression. Lee KS, **Rha SY**, Kim SJ, Kim JH, Roh JK, Kim BS, Chung HC. Clin Exp Metastasis. 1996 Nov;14(6):512-9.
367. Overexpression of c-ErbB-2 protein in gastric cancer by immunohistochemical stain. Lee HR, Kim JH, Uhm HD, Ahn JB, **Rha SY**, Cho JY, Lee JI, Lee KH, Chung HC, Roh JK, Min JS, Lee KS, Shin DH, Kim BS, Hong SW, Choi JH. Oncology. 1996 May-Jun;53(3):192-7.